Abstract book of the XIX Congress of the Italian Society of Experimental Hematology, Florence, 4-6 March 2026
No. 111 (s1)

SIES: Institutional Session

9

A01 | T-cell exhaustion in hematological malignancies

Lara Tavernari | Interdepartmental Centre for Stem Cells and Regenerative Medicine, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
https://doi.org/10.3324/haematol.2026.s1.1

A02 | Role of metabolic alterations in the marrow microenvironment in the response to immunotherapy in multiple myeloma

Michele Cea | Chair of Hematology, Department of Internal Medicine and Medical Specialties - DiMI, University of Genoa; IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
https://doi.org/10.3324/haematol.2026.s1.2

A03 | Pathogenetic significance of circulating biomarkers: the role of microvesicles

Lucia Catani | Istituto di Ematologia "L. e A. Seràgnoli", Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.
https://doi.org/10.3324/haematol.2026.s1.3

A06 | TP53 in myeloid neoplasms

Maria Teresa Voso, Luca Guarnera | Department of Biomedicine and Prevention, University of Rome Tor Vergata, Italy.
https://doi.org/10.3324/haematol.2026.s1.6

A08 | Clonal hematopoiesis, myeloid neoplasms and bone marrow failure syndromes

Enrico Attardi1|2 | 1 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; 2Department of Hematology, St. Jude Children’s Research Hospital, Memphis, USA
https://doi.org/10.3324/haematol.2026.s1.8

A09 | Defining the clonal complexity and biology of gene-modified hematopoiesis in gene therapy

Pamela Quaranta1, Guido Pacini1, Luca Seffin1|2, Luca Basso-Ricci1, Fabrizio Benedicenti1, Stefania Giannelli1, Ilaria Monti1, Clelia Perini1, Sara Mazza1, Silvia Darin3, Francesca Tucci3, Francesca Ferrua3, Valeria Calbi3, Andrea Calabria1, Eugenio Montini1, Maria Ester Bernardo1, Maria Pia Cicalese1|3, Alessandro Aiuti1|2|3, Serena Scala1 | 1San Raffaele Telethon Institute for Gene Therapy - SR-TIGET, San Raffaele Scientific Institute, Milan, Italy; 2Università Vita-Salute San Raffaele, Milan, Italy; 3Pediatric Immunohematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy.
https://doi.org/10.3324/haematol.2026.s1.9

SIES: Best Abstracts

7

B02 | Circulating plasma cells drive disease dissemination in multiple myeloma, independent of clonality

I. Vigliotta1, A. Varacalli1, M. Talarico1|2, V. Solli2, B. Taurisano2, S. Armuzzi2, I. Pistis1, V. M. Vuong2, A. Vitale1, G. Mazzocchetti2, E. Borsi1, A. Croce2, M. Martello2, A. Poletti2, C. Nanni3, K. Mancuso1|2, M. Puppi1|2, E. Zamagni1|2, C. Terragna1 | 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” 2Department of Medical and Surgical Sciences - University of Bologna; 3IRCCS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine
https://doi.org/10.3324/haematol.2026.s1.10

B03 | Clonal hematopoiesis in follicular lymphoma: analysis of the phase III FIL FOLL12 trial

N. Maher1|2, R. Moia2, M. Almasri2, E. Genuardi3, M. Drandi3, C. Cosentino2, R. Soscia4, Gm. Assanto4, A. Tucci5, C. Boccomini6, P. Corradini7, J. Olivieri8, L. Arcaini9|10, F. Ballerini11, F. Cavallo12, B. Puccini13, C. Patti14, C. Stelitano15, A. Pulsoni16, A. Santoro17, A. Pinto18, V.R. Zilioli19, L. Marcheselli20, S. Ciavarella21, R. Bomben22, S. Galimberti23, I. Del Giudice4, M. Ladetto1, G. Gaidano2, S. Luminari24, S. Ferrero3 | 1SCDU Ematologia, Department of Translational Medicine, AOU SS Antonio e Biagio E Cesare Arrigo, Università del Piemonte Orientale; 2Division of Hematology, Department of Translational Medicine, AOU Maggiore della Carità di Novara, Università del Piemonte Orientale; 3Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino; 4Hematology, Department of Translational and Precision Medicine, ‘Sapienza’ University of Rome – AOU Policlinico Umberto I; 5Division of Hematology, ASST Spedali Civili; 6Hematology Division, A. O. U. Città della Salute e della Scienza di Torino; 7Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori; 8Hematology and SCT Unit, Azienda Sanitaria Universitaria Integrata Santa Maria della Misericordia; 9Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia; 10Department of Molecular Medicine, University of Pavia; 11IRCCS Ospedale Policlinico San Martino; 12Division of Hematology, University Hospital A. O. U. "Città della Salute e della Scienza"; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Turin; 13Hematology Unit, Careggi University Hospital; 14Oncohematology Azienda Ospedali Riuniti Villa Sofia-V. Cervello Palermo; 15Grande Ospedale Metropolitano, Bianchi Melacrino Morelli, Ematologia Reggio Calabria; 16 Department of Hematology, SM Goretti Hospital, University Polo Pontino; 17 IRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology; 18 Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale'; 19 Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda; 20 Uffici Studi Fondazione Italiana Linfomi; 21Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II'; 22Centro di Riferimento Oncologico di Aviano; 23 Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa; 24 Ematologia, Azienda Unità Sanitaria Locale – IRCCS Reggio Emilia
https://doi.org/10.3324/haematol.2026.s1.11

B05 | Ectopic activation of FOXF1 and FENDRR by t(14;16)(q32;q24) identifies a high-risk T-ALL/MPAL subtype

D. Di Giacomo1|2|3, P. Pölönen1, V. Bardelli2, S. Kimura1, V. Pierini2, L. Pagliaro4, S. Arniani2, Y. Chang1, Q. Gao1, L. E. Montefiori1, C. Matteucci2, S. Lei1, W. Rosikiewicz5, C. Nardelli2, A. G. Lema Fernandez2, A. Østergaard1, E. A. Backhaus Wagner1, P. Baviskar1, M. Cerrano6, M. Leocin7, A. Manabe8, S. Hirabayashi8, J. Takita9, D. Hasegawa10, S. Miyamoto10, A. Macchiarulo11, J. Xu12|13, D.T. Teachey14, G. Roti4, I. Iacobucci1, R. La Starza2, C. Mecucci2, C. G. Mullighan1|15 | 1Department of Pathology, St. Jude Children's Research Hospital; 2Laboratory of Molecular Medicine CREO, Santa Maria della Misericordia Hospital and Department of Medicine and Surgery, University of Perugia; 3Department of Chemistry, Biology and Biotechnology, University of Perugia; 4Department of Medicine and Surgery, Translational Hematology and Chemogenomics THEC, University of Parma; 5Center for Applied Bioinformatics, St. Jude Children's Research Hospital; 6S. C. Ematologia, AOU Città della Salute e della Scienza - Presidio Molinette; 7Hematology Unit, Ospedale dell'Angelo; 8Department of Pediatrics, Hokkaido University Graduate School of Medicine; 9Department of Pediatrics, Graduate School of Medicine Kyoto University; 10Department of Pediatrics St. Luke's International Hospital; 11Department of Pharmaceutical Sciences, University of Perugia; 12Graduate Group in Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania; 13Medical Scientist Training Program, Perelman School of Medicine, University of Pennsylvania; 14Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; 15Center of Excellence for Leukemia Studies, St. Jude Children's Research Hospital
https://doi.org/10.3324/haematol.2026.s1.13

B06 | Integrating pharmacogenomics and microenvironment profiling in high-risk leukemias

M. Giaimo1|2|3, B. Cambò2, L. Pagliaro1|2|3, R. Zamponi1|3, R. Rosati1|3, D. Forte4, A. Gherli1|3, M. Crugnola2, L. Prezioso2, A. Rinaldi2, A. Pessina1|2, S. Bonomini2, G. Sammarelli2, A. Montanaro1|3, F. Pasini4, I.S. Polanco5, D. Ocadlikova5, A. Ferrari6, C. Salvesi6, A. Spedaluzzi6, M. Paganelli6, P. Tosi7, A. Tieghi8, D. Vallisa9, A. Cuneo10, F. Lanza4|11, G. Simonetti6, G. Martinelli4|5, A. Curti5, G. Roti1|2|3 | 1Department of Medicine and Surgery, University of Parma; 2Department of General and Specialist Medicine, Hematology and Hematopoietic Stem Cell Transplant, AOU di Parma; 3Translational Hematology and Chemogenomics “THEC”, University of Parma; 4Department of Medical and Surgical Sciences, University of Bologna; 5IRCCS AOU di Bologna, Istituto di Ematologia “Seràgnoli”; 6Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST “Dino Amadori”; 7Hematology Unit, Ospedale di Rimini; 8Department of Hematology, Azienda USL-IRCCS di Reggio Emilia; 9Department of Oncohematology, Ospedale “Guglielmo da Saliceto”; 10Department of Medical Sciences, University of Ferrara; 11Hematology Unit, Ospedale di Ravenna
https://doi.org/10.3324/haematol.2026.s1.14

B07 | Molecular risk profiling in myeloproliferative neoplasms blast phase treated with venetoclax and decitabine: a three-gene score for survival prediction

F. Crupi1|2|3, P. Guglielmelli1|2|3, F. Mannelli1|2|3, J. Caroprese1|2|3, M. Lomi1|3, G. G. Loscocco2|3, N. Bartalucci1|3, S. Soddu4, C. Maccari1|3, A. Enderti1|3, L. Signori1|3, A. Piciocchi4, P. Fazi4, A. M. Vannucchi1|2|3 | 1Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze; 2SOD Ematologia, AOU Careggi; 3Centro Ricerca e Innovazione Malattie Mieloproliferative CRIMM, AOU Careggi; 4Fondazione GIMEMA
https://doi.org/10.3324/haematol.2026.s1.15

B08 | Clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia: final results of the Prospective Flowers Study

A. Sicuranza1, P. Pacelli1, A. Santoni1 , E. Abruzzese2, D. Cattaneo3, A. Iurlo3, L. Luciano4, S. Galimberti5, V. Giai6, O. Mulas7, G. Caocci7, F. Sorà8, I. Capodanno9, M. Crugnola10, A. Gozzini11, S. Russo12, M. Annunziata13, C. Fozza14, A. Cartocci15, S. Fredducci1, E. Pacini1, A.M. Liberati16, M. Defina1, E. Bestoso1, C. Marzano1, D. Tocci1, T. Miracapillo1, C. Turriziani1, K. Peccia1, D. Raspadori1, M. Bocchia1 | 1Hematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese; 2Sant'Eugenio Hospital, Tor Vergata University; 3Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico; 4Hematology - Department of Clinical Medicine and Surgery, Federico II University; 5Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa; 6Division of Hematology, Città Della Salute e Della Scienza; 7Department of Medical Sciences and Public Health, University of Cagliari; 8Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore; 9SOC Ematologia Azienda USL-IRCSS di Reggio Emilia; 10Ematologia e Centro BMT, Azienda Ospedaliero-Universitaria di Parma; 11Hematology Unit, AOU Careggi, University of Florence; 12Hematology, University of Messina; 13Hematology Unit, Hospital 'Antonio Cardarelli'; 14Department of Medical, Surgical and Experimental Sciences, University of Sassari; 15Department of Medical Sciences, surgery and neurosciences, University of Siena; 16Università degli studi di Perugia - Struttura Complessa di Oncoematologia
https://doi.org/10.3324/haematol.2026.s1.16

SIES: Oral Communications

58

CO58 | Single-cell multi-omics unravels molecular and cellular programs underlying ruxolitinib response in myelofibrosis

C. Carretta1|2, S. Rontauroli1|2, M. Bertesi1|3, S. Parenti1|2, M. Maccaferri4, D. Benati1|3, M. Malerba1|3, A. Neroni1|3, E. Papa1|3, R. Norfo1|2, M. Mirabile1|3, L. Tavernari1|2, C. Tombari1|2, P. Guglielmelli5|6, A. Recchia1|3, L. Potenza4|7, E. Tagliafico7|8, M. Luppi4|7, A. Vannucchi5|6, R. Manfredini1|2 | 1Interdepartmental Centre for Stem Cells and Regenerative Medicine, University of Modena and Reggio Emilia; 2Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia; 3Department of Life Sciences, University of Modena and Reggio Emilia; 4Department Oncology and Hematology, Hematology Unit, Modena University Hospital; 5CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence; 6Department of Experimental and Clinical Medicine, University of Florence; 7Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia; 8Department of Laboratory Medicine, Diagnostic Hematology and Clinical Genomics Unit, Modena University Hospital

CO42 | Dynamic changes after allogeneic stem cell transplantation of extracellular vesicles originated from platelets, endothelial cells and leukocytes after: correlation with acute graft-versus-host disease

G. Lia1|2, A. Melis1|2, F. Ferrando1|2, M. Dicataldo1|2, A. Martin1|2, A. Evangelista4, I. Dogliotti1, C.M. Dellacasa3, A. Busca3, B. Bruno1|2, L. Giaccone1|2 | 1Stem Cell Transplant Program, Department of Oncology, A. O. U. Città della Salute e della Scienza di Torino; 2Department of Molecular Biotechnology and Health Sciences, University of Torino; 3University Hospital A. O. U. "Città della Salute e della Scienza di Torino", Division of Hematology; 4Clinical Epidemiology, A. O. U. Città della Salute e della Scienza di Torino

CO43 | Fourier-transform infrared spectroscopy of plasma as a liquid biopsy for monitoring acute myeloid leukemia and extramedullary relapse following allo-HSCT

A. Leoni1|2, B. Xhahysa1|2, L. Garuffo1|2, A. Cavalleri1|2, F. Trenta1|2, F. Re1|2, S. Mutti1|2, L. Paolini3|4, M. Farina2, E. Morello2, D. Avenoso2, D. Russo2, M. Malagola2, S. Bernardi1|2 | 1Centro di Ricerca Emato-oncologico AIL, ASST Spedali Civili di Brescia; 2Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia; 3Department of Medical and Surgical Specialties, Radiological Sciences and Public Health - DSMC, University of Brescia; 4Center for Colloid and Surface Science -CSGI- Sesto Fiorentino. .

CO 45 | Targeting IDO1 and ATP catabolism overcomes the tolerogenic effects of cytarabine on acute myeloid leukemia immune microenvironment

D. Ocadlikova1, P. Portararo2, E. Adinolfi3, E. De Marchi3, A. Pegoraro3, E. Orioli3, S. Sangaletti2, A. Curti1 | 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 2Fondazione IRCCS, Istituto Nazionale dei Tumori; 3Department of Medical Sciences, University of Ferrara, Italy.

CO46 | BCR-ABL1 and JAK2v617f mutations in mesoangiogenic progenitor cells suggest a common bone marrow precursor for hematopoietic and stromal cell niche

I.S. Burzi1, M. Montali2, S. Barachini2, E. Pardini1, G. Sardo Infirri1, D. Tagliafierro1, A. Brunetti2, A. Votto2, L. Sijoni2, R. Fazzi3, S. Galimberti2, V. Susini1, M. Franzini1, I. Petrini1 | 1Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, Università di Pisa; 2Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa; 3U. O. Ematologia, A. O. U. Pisana, Italy.

CO47 | Exploring the role and cellular origin of extracellular vesicles as biomarkers in CAR-T cell therapy

G. Lia1|2, M. Dicataldo1|2, A. Melis1|2, F. Ferrando1|2, I. Dogliotti2, A. Busca2, S. Ragaini1, V. Granero3, B. Botto4, M. Clerico5, M. Novo4, F. Cavallo6, L. Giaccone6, B. Bruno6 | 1Department of Molecular Biotechnology and Health Sciences, University of Torino; 2Stem Cell Transplant Program, AOU Città della Salute e della Scienza di Torino;3 Blood Bank, Immunohaematology and Transfusion Medicine Center; A. O. U. Città della Salute e della Scienza di Torino; 4Division of Hematology, AOU Città della Salute e della Scienza di Torino; 5Division of Hematology U, A. O. U. Città della Salute e della Scienza di Torino; 6Division of Hematology U, Department of Molecular Biotechnology and Health Sciences, University of Torino

CO49 | Combined nf1/suz12 haploinsufficiency drives aberrant activation of the RAS signaling cascade in immature hoxa-positive T-ALL

V. Bardelli1, L. Pagliaro2, V. Pierini3, S. Arniani1, F. Servoli1, M. Lucarelli1, S. Sica4, M. Cerrano5, F. Giglio6, M. Delia7, B. Cambo’8, M. Annunziata9, S. Trappolini10, F. Forghieri11, M. Lunghi12, P. Zappasodi13, M. Piccini14, C. Matteucci1, A. Tafuri15, P. Grammatico16, Mp. Martelli1, C. Mecucci1, G. Roti2, R. La Starza1 | 1Hematology and Bone Marrow Transplantation Unit, Department of Medicine and Surgery, University of Perugia; {2}Department of Medicine and Surgery, University of Parma, Parma, Italy; Hematology and BMT Unit, Azienda Ospedaliero Universitaria di Parma, Parma, Italy, Translational Hematology and Chemogenomics, University of Parma; {3}Laboratory of Molecular Medicine and Cytogenetics. Hematology Unit, CREO, Azienda Ospedaliera di Perugia; {4}Dipartimento di Scienze di Laboratorio ed Ematologiche-Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore; {5}Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin; {6}Hematology and Bone Marrow Transplantation Unit, IRCCS Ospedale San Raffaele; {7}Hematology and Stem Cell Transplantation Unit, AOUC Policlinico of Bari; {8}Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma; {9}Hematology Unit, Hospital 'Antonio Cardarelli'; {10}Hematology Clinic, Azienda Ospedaliero Universitaria delle Marche; {11}Section of Hematology, Department of Oncology and Hematology. Azienda Ospedaliero-Universitaria di Modena; {12}University of Piemonte Orientale; {13}Division of Hematology, Foundation, IRCCS Policlinico San Matteo, Pavia; {14}SOD Hematology, University of Florence, AOU Careggi; {15}Hematology, Department of Biotecnologie Cellulari ed Ematologia, Sapienza, University of Rome; {16}Division of Medical Genetics, Department of Experimental Medicine, San Camillo-Forlanini Hospital, Sapienza University

CO 50 | Redefining FLT3 in B-ALL novel findings and therapeutic outlook

A. Ferrari1, F. Lo Schiavo1, C. Salvesi1, L. Ledda1, M. Paganelli1, A. Spedaluzzi1, M. C. Papayannidis2, G. Marconi3, M. Rondoni4, Am. Mianulli5, B. Giannini6, C. Pasciolla7, F. Giglio8, S. Galimberti9, M. Fumagalli10, P. Salutari11, V. Gaidano12, Mb. Giannini13, A. Imovilli14, E. Mauro15, E. Fonzi16, A. Ghelli Luserna Di Rorà17, G. Martinelli18, G. Simonetti1 | 1Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori - IRST "Dino Amadori"; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 3University of Bologna, Hematology Unit, S. Maria delle Croci hospital; 4Hematology Unit & Romagna Transplant Network, S. Maria delle Croci hospital; 5Hematology, Infermi Hospital; 6U. O. Genetica Medica, Laboratorio Unico- AUSL della Romagna, Italy; 7Hematology and Bone Marrow Transplantation Unit, Istituto Oncologico IRCCS “Giovanni Paolo II”; 8Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute; 9Hematology Unit, AOUP Santa Chiara; 10Hematology Unit, Ospedale San Gerardo; 11Dipartimento Oncologia Ematologia, Ospedale Civile Santo Spirito; 12SCDU Ematologia e Terapie cellulari, A. O. Ordine Mauriziano; 13Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST"Dino Amadori"; 14Hematology, Azienda USL-IRCCS Reggio Emilia, Emilia-Romagna, Italy; 15UOC Ematologia Ospedale Ca' Foncello Azienda ULSS 2 Marca Trevigiana; 16 Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST"Dino Amadori"; 17 Fondazione Pisana per la Scienza ONLUS; 18 University of Bologna, Istituto di Ematologia “Seràgnoli”

CO51 | Pediatric PAX5-rearranged acute lymphoblastic leukemia is a high-risk molecular subgroup of B-ALL with a poor MRD-dependent prognostic profile

N. Peccatori1|2|3, A. Curto2|3, D. Silvestri2, S. Rebellato2, Ž. Antić4/5, S. Bhatia6, A. K. Bergmann4|5, A. Borkhardt6, M. Zimmermann7, S. Strehl8, K. Nebral8|9, C. Saitta1, M. Quadri2, C. Palmi2, M. Bardini2, D. Guardo10, L. Lo Nigro11, R. Parasole12, M.C. Putti13, F. Locatelli14|15, J. Alten16, M. Stanulla7, M. G. Valsecchi3, B. Buldini13, V. Conter2, A. Biondi2|3, A. Balduzzi1|3, M. Schrappe16, A. Attarbaschi8|17, G. Cario16, C. Rizzari1|3, G. Cazzaniga2|3, G. Fazio2|3 | 1Pediatrics, Fondazione IRCCS San Gerardo dei Tintori; 2Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori; 3School of Medicine and Surgery, University of Milano-Bicocca; 4Department of Human Genetics, Hannover Medical School; 5Clinical Genetics and Genomic Medicine, University Hospital Würzburg; 6Department for Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine University; 7Department of Paediatric Haematology and Oncology, Hannover Medical School; 8St. Anna Children's Cancer Research Institute; 9Labdia Labordiagnostik; 10Unit of Hematology, IRCCS Istituto Giannina Gaslini; 11Pediatric Hematology Oncology, Azienda Policlinico "G. Rodolico"; 12Dept. Oncology, Hematology and Cell Therapy, AORN, Santobono-Pausilipon; 13Istituto di Ricerca Pediatrica-Città della Speranza, Pediatric Onco-Hematology, Stem Cell Transplant and Gene Therapy Laboratory; 14Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù; 15Department of Pediatrics, Catholic University of the Sacred Heart; 16University Medical Center Schleswig-Holstein- Campus Kiel, Department of Pediatrics- Berlin-Frankfurt-Münster ALL Study Group Germany BFM-G; 17Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital. .

CO52 | Deciphering the crosstalk between stroma and acute myeloid leukemia cells: an in vitro model to uncover the mechanisms underlying extramedullary progression in acute myeloid leukemia

G. Silvestrini1, N. Lelli1, S. Masciarelli2, G. Mazzanti2, F. Liccardo2, L. Guarnera3, M. Divona1|4, P. Ricci1, Ma. Irno Consalvo1, G. Colafranceschi1, S. Gargiulo1, F. Fazi2, T. Ottone1|5 and Mt. Voso1|5 | 1Department of Biomedicine and Prevention, Tor Vergata University; 2Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Section of Histology and Medical Embryology, Sapienza University of Rome; 3Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata; 4Saint Camillus International University of Health Sciences; 5Santa Lucia Foundation, IRCCS, Neuro-Oncohematology, Italy.

CO53 | Targeting the PA2G4-NPM1 axis triggers nucleolar stress in NPM1c acute myeloid leukemia

E. Simoncini1, R. Zamponi2, A. Montanaro1, R.M. Poldi Allay Patarino1, F. Vento1, A. Gherli1, V. Marinoni1, B. Lorusso1, R. Rosati1, G. Monica1, R. Castelli3, A. Andolfo4, C. Braccia4, A. Lodola3, G. Roti1|2 | 1Department of Medicine and Surgery, University of Parma; 2Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma; 3Department of Food and Drug, University of Parma; 4ProMeFa, Proteomics and Metabolomics Facility, Center for Omics Sciences, IRCCS San Raffaele Scientific Institute

CO54 | Biallelic loss of RB1 and LPAR6 at 13q14 drives key cell cycle abnormalities in T-cell acute lymphoblastic leukemia

F. Servoli1, M. Giaimo2, V. Pierini3, V. Bardelli1, S. Arniani1, M. Lucarelli1, C. Matteucci1, B. Crescenzi3, S. Romoli3, L. Pagliaro2, R. Zamponi2, A. Fiou4, M. Vecchi5, F. Landuzzi4, F. Forghieri6, A. Curti7, B. Cambò2, C. Pasciolla8, F. Lessi9, F. Lussana10, A. Cavalli4|11|12, G. Roti2, M.P. Martelli1, R. La Starza1 | 1Hematology and Bone Marrow Transplantation Unit, Department of Medicine and Surgery, University of Perugia; 2Department of Medicine and Surgery, University of Parma; Hematology and BMT Unit, Azienda Ospedaliero Universitaria di Parma; Translational Hematology and Chemogenomics THEC, University of Parma; 3Laboratory of Molecular Medicine and Cytogenetics. Hematology Unit, CREO, Azienda Ospedaliera di Perugia; 4Center for Clinical and Computational Genomics, Computational and Chemical Biology, Fondazione Istituto Italiano di Tecnologia IIT; 5Center for Clinical and Computational Genomics, Non-coding RNAs and RNA-based therapeutics, Fondazione Istituto Italiano di Tecnologia IIT; 6Section of Hematology, Department of Oncology and Hematology. Azienda Ospedaliero-Universitaria di Modena; 7IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 8Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 9Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova; 10Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII; 11Center for Human Technologies, Computational and Chemical Biology, Fondazione Istituto Italiano di Tecnologia IIT; 12Centre Européen de Calcul Atomique et Moléculaire CECAM, Ecole Polytechnique Fédérale de Lausanne

CO55 | Integrating NGS and optical genome mapping to improve genomic characterization of adult BCR:ABL1-negative B-ALL

L. Bonamici1, B. Conte1, E. Sbadili1, G. Fera1, C. Meli2, G. Debbia1, P. Barozzi1, A. Paolini3, S. Martinelli3, M. Morselli1, L. Potenza1, D. Giusti1, E. Colaci1, F. Bettelli1, P. Bresciani1, A. Cuoghi1, A. Gilioli1, A. Messerotti1, V. Pioli1, R. Manfredini4, F. Forghieri1, M. Luppi1, F. Lussana2, O. Spinelli5, R. Maffei3, A. Rambaldi2, E. Tagliafico3 | 1Hematology Unit, and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico; 2Department of Oncology and Hematology, University of Milan and ASST Papa Giovanni XXIII; 3Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, Azienda Ospedaliero-Universitaria, Policlinico; 4Interdepartmental Centre for Stem Cells and Regenerative Medicine and Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia; 5Department of Oncology and Hematology, ASST Papa Giovanni XXIII

CO56 | Integration of multiple RNA-seq datasets enhances deep profiling of NPM1-mutated FLT3-ITD-negative acute myeloid leukemia

M. Caridi1|2, G. Cimino3, W. Villiers4, M. Lim4, F. Milano3, S. De Santis3, R. Ranieri3, V. Cardinali3, P. Aucken4, R. Dillon4, M.P. Martelli3 | 1Hematology Unit, Belcolle Hospital; 2Department of Physiology and Pharmacology, Sapienza University of Rome; 3Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 4Department of Medical and Molecular Genetics, King’s College London, UK.

CO57 | Molecular characterization of a cohort of patients with polycythemia vera: a single-center study

E. Nacca, C. Ghetti, F. Vanderwert, V. Boldrini, L. Fagiolo, G. Rotunno, L. Signori, C. Basile, F. Gesullo, A. Enderti, Am. Vannucchi, P. Guglielmelli | Department of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative - CRIMM, AOU Careggi, University of Florence, Italy.

CO41 | Monocyte activation by CAR-T cells: role of extracellular vesicles and secretome in immune modulation

B. Xhahysa1, M. Farina2, I. Grossi3, L. Garuffo1, R.M. Ferraro3, A. Leoni1, A. Cavalleri1, S. Mutti1, F. Trenta1, F. Re1, E. Morello2, D. Avenoso1|2, P. Balzarini3, A. Salvi3, M. Malagola1|2, D. Russo1|2, S. Bernardi1 | 1Department of Clinical and Experimental Sciences, University of Brescia; 2Unit of Blood Diseases and BMT, ASST Spedali Civili of Brescia; 3Department of Molecular and Translational Medicine, University of Brescia, Italy.

CO59 | JAK2 46/1 haplotype and JAK2 variant allelic frequency correlate with the development of polycythemic phenotype in JAK2-mutated essential thrombocytemia patients

G. Capecchi1|2, C. Maccari1|2, L. Signori L1|2, G.G. Loscocco1|2, V. Boldrini1|2, G. Borgi G1|2, G. Rotunno1|2, F. Gesullo1|2, E. Nacca1|2, S. Pestelli2, I. Sestini1, T. Barbui3, A.M. Vannucchi1|2, P. Guglielmelli1|2 | 1CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence; 2Department of Experimental and Clinical Medicine, University of Florence; 3FROM Ospedale Papa Giovanni XXIII

CO60 | One hundred suspected myeloproliferative neoplasms with a JAK2 v617f variant allele frequency <2%: clinical, genetic and histopathological correlates

G.G. Loscocco1, R. Santi2, G. Rotunno1, L. Signori1, F. Gesullo1, F. Pancani1, C. Maccari1, V. Boldrini1, P. Guglielmelli1, U. Gianelli3, A.M. Vannucchi1 | 1Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence; 2Hemopathology Unit, AOU Careggi, University of Florence; 3Pathology Unit, ASST Santi Paolo e Carlo, University of Milan

CO61 | Transcriptomic analysis of CD34⁺ cells in myelofibrosis highlights their role in extracellular matrix dysregulation and marrow fibrosis

S. Bernardi 1, L. Garuffo 1, M. Farina 1, G. Pozzi 2, L. M. Pasini 3, S. Cortellazzi 2, A. Leoni 1, O. Di Martino 2, F. Arciprete 4, M. Zingariello 4, M. Vitale 5, D. Russo 1, C. Carubbi 2, E. Masselli 2|3 | 1Department of Clinical and Experimental Sciences, University of Brescia, Unit of Cell Therapy and Bone Marrow Transplantation, ASST Spedali Civili of Brescia 2Department of Medicine and Surgery, Anatomy Unit, University of Parma; 3Hematology and BMT Unit, Parma University Hospital AOUPR; 4Laboratory of Microscopic and Ultrastructural Anatomy, Campus Bio-Medico University of Roma; 5Faculty of Medicine, Vita-Salute University-San Raffaele, Italy.

CO62 | CD9 defines the disease-propagating hematopoietic stem cell population in myelofibrosis

R. Norfo1|2, L. Tavernari1|2, A. Neroni1|3, C. Tombari1|2, S. Rontauroli1|2, M. Mirabile1|2, E. Genovese1, M. Maccaferri4, G. Grisendi5, C. Carretta1|2, S. Parenti1|2, L. Fabbiani5, M. Bertesi1|3, E. Papa1|2, M. Malerba1|2, L. Potenza4|5, L. Losi5, P. Guglielmelli6|7, M. Dominici5, M. Luppi4|5, E. Tagliafico5|8, A.M. Vannucchi6|7, R. Manfredini1|2 | 1CIDSTEM, Interdepartmental Centre for Stem Cells and Regenerative Medicine, University of Modena and Reggio Emilia; 2Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia; 3Department of Life Sciences, University of Modena and Reggio Emilia; 4Department of Laboratory Medicine and Pathology, Diagnostic Hematology and clinical Genomics Unit, Modena University Hospital; 5Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia; 6CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence; 7Department of Experimental and Clinical Medicine, University of Florence; 8Department of Laboratory Medicine, Diagnostic Hematology and Clinical Genomics Unit, Modena University Hospital

CO63 | abcg2 and havcr2 SPNs are associated with long-term TFR maintenance in chronic myeloid leukemia patients

S. Di Giusto1, C. Cozzarolo1, T. Liani2, M. Moro2, A. Ermacora3, R. Stella4, F. Zaja4|5 R. Fanin1|2, D. Damiani1|2, M. Tiribelli1|2, E. Toffoletti1|2 | 1Division of Hematology and Bone Marrow Transplant, Azienda Sanitaria Universitaria Friuli Centrale; 2Department of Medicine, University of Udine; 3Hematology Unit, Azienda Sanitaria Friuli Occidentale; 4Hematology Unit, Azienda Sanitaria Universitaria Giuliano-Isontina; 5Department of Medical, Surgical and Health Sciences, University of Trieste

CO64 | Dissecting the role of CCL2/CCR2 axis in myelofibrosis: translational evidence from murine models to human cells

L.M. Pasini1, G. Pozzi2, O. Di Martino2, S. Cortellazzi2, R. Vairo2, C. Micheloni2, F. Arciprete3, M. Zingariello3, S. Bernardi4, A.R. Migliaccio5|6, M. Vitale7, C. Carubbi2, E. Masselli1|2 | 1Parma University Hospital, Hematology and BMT Unit; 2Department of Medicine and Surgery, University of Parma; 3Campus Bio-Medico University of Rome; 4Department of Clinical and Experimental Sciences, University of Brescia; 5Altius Institute for Biomedical Sciences; 6Nanotec-CNR; 7Faculty of Medicine, Vita-Salute University-San Raffaele, Italy.

CO65 | Clinical impact of untargeted baseline plasma metabolomics in newly diagnosed diffuse large B-cell lymphoma

M. Almasri1, R. Dondolin1, D. Marradi2, E. Barberis2, L. T. Di Bergamo3, C. Cosentino1, A. Bruscaggin3, M. Salehi3 , R. Bruna1, M. Bellia1, M. Schipani1, J. Nabki1, B. Al Deeban1, L. Cividini1, S. Mouhssine1, N. Maher1, J. Ghanej1, F. Maiellaro1, A. andorno4, F. Mercalli4, E. Martino5, A.M. Mahmoud1, W. Al Essa1, N. M. Diop1, E. Secomandi1, C. Deambrogi1, S. Rasi1, R. L. Boldorini4, M. Gentile5, G.A. Palumbo6, V. Gattei7, R. Foà8, D. Rossi3, M. Manfredi2, G. Gaidano1, R. Moia1 | 1Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale; 2Center for Translational Research on Autoimmune and Allergic Diseases CAAD, University of Piemonte Orientale; 3Laboratory of Experimental Hematology, Institute of Oncology Research; 4Division of Pathology, Department of Health Sciences, Università del Piemonte Orientale; 5Hematology Unit AO of Cosenza; 6Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G. F. Ingrassia", University of Catania; 7Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano CRO IRCCS; 8Hematology, Department of Translational and Precision Medicine, ‘Sapienza’ University

CO67 | Secondary genetic events and their relationship to TP53 mutation in mantle cell lymphoma. A sub-study from the Fondazione Italiana Linfomi Mantle First-BIO study

M.E. Carazzolo1|3, F.M. Quaglia2, A. Aparo3, A. Moioli2, A. Parisi4, R. Moia5, F. Piazza6, A. Re7, M.C. Tisi8, L. Nassi9, P. Bulian10, A. Castellino11, V.R. Zilioli12, P.M. Stefani13, A. Fabbri14, E. Lucchini15, A. Arcari16, L. Lorenzi17, B. Famengo18, M. Ponzoni19, A. Ferrari 20, S. Ragaini21, J. Olivieri22, V. Salaorni23, S. Gambino2|24, M. Galasso2|24, M.T. Scupoli3|24, C. Visco2|24 | 1Department of Medicine, University of Verona; 2UOC di Ematologia, DAI Medico Generale, AOUI Verona; 3Research Center LURM Interdepartmental Laboratory of Medical Research, University of Verona; 4Department of Pathology and Diagnostics, University Hospital of Verona; 5Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and AOU Maggiore della Carità di Novara; 6Department of Medicine, University of Padova and Unit of Hematology, Azienda Ospedale Università Padova; 7UOC Ematologia, Spedali Civili di Brescia; 8Hematology Unit, San Bortolo Hospital, Vicenza; 9Hematology, Careggi Hospital and University of Florence; 10Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico; 11Hematology Unit, AO Santa Croce e Carle, Cuneo; 12Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan; 13Struttura Complessa di Ematologia, Dipartimento Strutturale di Medicina Interna. Presidio Ospedaliero di Treviso; 14UOC Ematologia, Azienda Ospedaliero-Universitaria Senese; 15UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste 16Unità Operativa Complessa di Ematologia, Azienda USL di Piacenza, Ospedale Guglielmo da Saliceto, Piacenza; 17Department of Histopathology, University of Brescia, ASST Spedali Civili di Brescia; 18Pathology Department, San Bortolo Hospital; 19Vita Salute San Raffaele University and Pathology Unit, San Raffaele Hospital Scientific Institute, Milan; 20Hematology, Azienda USL-IRCCS di Reggio Emilia; 21Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino; 22Hematology Clinic, ASUFC Udine; 23Department of Diagnostic and Public Health, University of Verona; 24Department of Engineering for Innovation Medicine, Section of Biomedicine, University of Verona

CO68 | Genomic analyses of patients with mantle cell lymphoma that were refractory or relapsed after induction therapy: results from the Fondazione Italiana Linfomi Mantle First-BIO study

F.M. Quaglia1, M.E. Carazzolo2, A. Aparo3, A. Parisi4, R. Moia5, F. Piazza6, A. Re7, M.C. Tisi8, L. Nassi9, P. Bullian10, A. Castellino11, V.R. Zilioli12, P.M. Stefani13, A. Fabbri14, F. Zaja15, A. Arcari16, L. Lorenzi17, B. Famengo18, M. Ponzoni19, A. Ferrari20, S. Ferrero21, J. Olivieri22, M.T. Scupoli3|23, V. Salaorni24, S. Gambino23, M. Galasso23, C. Visco23 | 1UOC di Ematologia, DAI Medico Generale, AOUI Verona; 2Department of Medicine, University of Verona; 3Research Center LURM Interdepartmental Laboratory of Medical Research, University of Verona; 4Department of Pathology and Diagnostics, University Hospital of Verona; 5Università del Piemonte Orientale; 6Hematology Division, Department of Medicine, University of Padova; 7UOC Ematologia, Spedali Civili di Brescia; 8Hematology Unit, San Bortolo Hospital; 9Hematology Unit, Careggi University Hospital; 10Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico; 11Hematology Unit, Santa Croce E Carle Hospital;12Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano 13Struttura Complessa di Ematologia, Dipartimento Strutturale di Medicina Interna. Presidio Ospedaliero di Treviso; 14Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena; 15Department of Medical, Surgical and Health Sciences, University of Trieste; 16Unità Operativa di Ematologia, Ospedale Guglielmo da Saliceto; 17Department of Histopathology, University of Brescia, ASST Spedali Civili di Brescia; 18Pathology Department, San Bortolo Hospital; 19Ospedale S. Raffaele H. Scientific Institute; 20Hematology, Azienda USL-IRCCS di Reggio Emilia; 21Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino; 22Hematology Clinic, ASUFC Udine; 23Department of Engineering for Innovation Medicine, Section of Biomedicine, University of Verona; 24Department of Diagnostic and Public Health, University of Verona

CO69 | PRDM1 and TNFAIP3 copy number losses predict a shorter time to first treatment in igm gammopathies: new insights from the Fondazione Italiana Linfomi “BIO-WM” trial

M. Pironti1, S. Ferrero1|2, S. Zimbellini3, L. Marcheselli4, S. Russo1, E. Genuardi1, C. Varraso3, F. Cavallo1|2, I. Dogliotti2, E. Cappello3, S. Ragaini1, G. Favrin3, A. Ferrari5, M. Coscia6, C. Jimenez7, B. M. Granelli8, L. Laurenti9, E. Cencini10, S. Tommassetti11, D. Marino12, G. Loseto13, M. Marchetti14, F. Russo15, A. Sica16, J. Olivieri17, E. Amaducci1, C. Picone3, B. Bruno1|2, M. Varettoni3, D. Drandi1 | 1Department of Molecular Biotechnology and health sciences, Hematology Division, University of Torino; 2Division of Hematology, A. O. U. Città della Salute e della Scienza di Torino, Torino; 3Fondazione IRCCS Policlinico San Matteo; 4Fondazione Italiana Linfomi; 5Ematologia - AO Arcispedale Santa Maria Nuova - IRCCS; 6Department of Medicine and Surgery, University of Insubria and Division of Hematology ASST Sette Laghi; 7Haematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca CIBERONC and Center for Cancer Research-IBMCC; 8ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia; 9Ematologia - Università Cattolica S. Cuore; 10U. O. C. Ematologia, AOU Senese; 11Ematologia - Ospedale degli Infermi di Rimini; 12Oncologia 1 - I. R. C. C. S. Istituto Oncologico Veneto; 13U. O. C Ematologia, IRCCS Istituto Tumori Giovanni Paolo II; 14S. O. S. Ematologia, Ospedale Cardinal Massaia; 15AOU di Parma - UOC Ematologia e CTMO; 16AOU Universitа degli Studi della Campania Luigi Vanvitelli - Oncologia Medica ed Ematologia; 17Azienda Sanitaria Universitaria Friuli Centrale - SOC Clinica Ematologica

CO70 | Comparative assessment of targeted next-generation sequencing panels and algorithms for optimal molecular subtyping of diffuse large B-cell lymphoma in clinical practice

D. Gallucci1, M.C. Vegliante2, G. Gargano3, A. Ferri1, L. Pasini1, S. Lonardi1, G. Mandelli1, D. Medicina1, P. Balzarini1, V. Pellegrini1, W. Vermi1, C. Re1, P. Bossini1, A. Sanzogni1, E. Albertini1, A. Tucci4, A. Re4, M. Pizzi5, A. Di Napoli6, F. Cordero7, L. Lorenzi1, S. Ciavarella2. | 1Anatomia Patologica, ASST Spedali Civili di Brescia e DMMT Università degli Studi di Brescia; 2Hematology; and Cell Therapy Unit, IRCCS-Istituto Tumori "Giovanni Paolo II"; 3Dipartimento di Bioscienze, Biotecnologie e Ambiente, Università degli Studi di Bari Aldo Moro; 4Ematologia, ASST Spedali Civili di Brescia; 5Anatomia Patologica, Azienda Ospedaliera Universitaria di Padova; 6Dipartimento di Medicina Clinica e Molecolare, Ospedale Universitario Sant'Andrea, Sapienza Università di Roma; 7Dipartimento di Informatica, Università degli Studi di Torino

CO19 | Identification by a single cell analysis of CCN5/Wisp2 as a possible marker of the osteogenic impairment in the myeloma bone microenvironment

C. Sitzia1, M. Dessena1, F. Mohammadi1, T. Torelli2, C. Manferdini3, A. Guidi2, R. Vescovini1, D. Toscani4, A. Poletti1, N.T. Iannozzi1, V. Raimondi1, O. Lungu1, S. Ricci4, G. Todaro4, G. Sammarelli4, B. Dalla Palma4, G. Lisignoli3, L. Agnelli2, N. Giuliani1|4, P. Storti1 | 1Dipartimento di Medicina e Chirurgia, Università di Parma; 2Dipartimento di Diagnostica Innovativa, IRCCS Istituto Nazionale dei Tumori; 3Laboratorio di Immunoreumatologia e Rigenerazione Tissutale, IRCCS Istituto Ortopedico Rizzoli; 4U. O. Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma Programma Dipartimentale Mieloma Multiplo e Gammopatie Monoclonali, Italy.

CO02 | Genomic screening of primary refractory acute myeloid leukemia without TP53 alterations by optical genome mapping

R. Maffei1, S. Martinelli1, B. Conte2, F. Bettelli2, L. Bonamici2, P. Barozzi2, A. Paolini1, F. Giacobbi1, G. Corradini1, F. Pilato1, G. Debbia2, S. Cordella2, A. Cassanelli2, F. Cretì2, M. Morselli2, L. Potenza2, D. Giusti2, E. Colaci2, P. Bresciani2, A. Cuoghi2, A. Gilioli2, A. Messerotti2, V. Pioli2, M. Maccaferri2, G. Leonardi2, R. Marasca2, A. Candoni2, F. Forghieri2, M. Luppi2, E. Tagliafico1 | 1Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, Azienda Ospedaliero-Universitaria, Policlinico; 2Hematology Unit, and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico

CO03 | Functional study of circRNA with altered expression in T-ALL and circRNA-driven T-ALL subtype classification

A. Caregari1|2, S. Habibi Anjedani3|2, E. Gaffo1, A. Cani3, G. Veltri3, E. Rampazzo4, A. Teramo4, S. Hu5, J. Kluiver5, B. Buldini3|6, V. Serafin3|7, S. Bresolin3, S. Bortoluzzi1 | 1Computational Genomics Group, Department of Oncology, Surgery and Gastroenterology, University of Padua; 2Department of Biology, University of Padua; 3Pediatric hematology, oncology and hematopoietic cell & gene therapy, Pediatric Research Institute, Città della Speranza; 4Department of Molecular Medicine, University of Padua; 5Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen; 6Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padua; 7Department of Biomedical, Metabolic and Neural Sciences, Cellular Signalling Unit, University of Modena and Reggio Emilia.

CO05 | Identification of wnk1 as a druggable target in TAL1-related T-cell acute lymphoblastic leukemia

A. Montanaro1, G. Monica1, A. D’antuono1, R. Zamponi2, G. Sammarelli2, G. Todaro2, R. La Starza2, C. Mecucci3, M. Giaimo1, A. Gherli1, F. Vento1, Bruno Lorusso1, E. Simoncini1, L. Pagliaro1|2, C. R. Jimenez4, F. Quaini1, G. Roti1|2 | 1Department of Medicine and Surgery, University of Parma, Parma, Italy; 2Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Italy; 3Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria Della Misericordia Hospital, Perugia, Italy; 4OncoProteomics Laboratory, Cancer Center Amsterdam, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands

CO07 | Single-cell sequencing reveals pathways and perturbations predictive of central nervous system dissemination in B-cell acute lymphoblastic leukemia

L.V. Cappelli1, F. Iannelli2, D. Cardinali1|5, L. Fumagalli2, A. Natoni1, F. Kaiser1, M. Di Trani1, S. Chiaretti1, R. Chiarle2|3|4, S. Pileri2, R. Foà1 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University; 2Division of Hematopathology, IEO European Institute of Oncology IRCCS; 3Department of Pathology, Children's Hospital and Harvard Medical School; 4Department of Molecular Biotechnology and Health Sciences, University of Torino

CO08 | Flt3 as a new therapeutic target in preclinical models of pediatric BCP-ALL with PAX5 rearrangement

A. Curto1|2, N. Peccatori1|2, S. Rebellato1, R. Rapisarda1, S. Bhatia3, A. Borkhardt3, C. Palmi1, M. Bardini1, A. Biondi1, G. Cazzaniga1|2|4, G. Fazio1|2 | 1Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori; 2School of Medicine and Surgery, University of Milano Bicocca; 3Department of Paediatric Oncology, Haematology and Clinical Immunology, Heinrich-Heine and University Dusseldorf, Medical Faculty; 4Medical Genetics, School of Medicine and Surgery, University of Milan Bicocca

CO10 | Spatial transcriptomic analysis of chronic lymphocytic leukemia lymph nodes reveals tumor microenvironment evolution during disease progression

G. Notarpietro1, A. Bucci1, M.C. Vegliante1, B. Apollonio2, S.A. Pappagallo1, P. Mondelli1, R. Daprile3, A. Scattone3, M. Frenquelli4, A. Guarini1, G. Castellano5, A. Ciarrocchi6, B. Donati6, M. Ponzoni7, P. Ghia8, C. Minoia1 | 1IRCCS Istituto Tumori "Giovanni Paolo II", Hematology Unit; 2IRCCS Istituto Tumori "Giovanni Paolo II", Rare Tumors and Melanoma Unit; 3IRCCS Istituto Tumori "Giovanni Paolo II", Pathology Unit; 4San Raffaele Scientific Institute, B-cell Neoplasia Unit Division of Experimental Oncology; 5Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS; 6Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia; 7Medical School, Università Vita-Salute San Raffaele; 8Comprehensive Cancer Center, IRCCS Ospedale San Raffaele

CO11 | BCOR inactivation in B cells initiates CLL-like disease and enables study of disease evolution in a novel mouse model

Daniele Sorcini1, A. Stella1, F.M. Adamo1, F. De Falco1, R. Arcaleni1, F. Gurrieri1, E. Dorillo1, A. Esposito1, L. Valmarini1, A. Atzeni1, B. Bigerna2, M.P. Martelli1|2, P. Sportoletti1|2 | 1Department of Medicine and Surgery, Institute of Hematology and Center for Hemato-Oncology Research CREO, University of Perugia and Santa Maria della Misericordia Hospital; 2Santa Maria della Misericordia Hospital

CO12 | Epigenetic regulation of CD49d expression in chronic lymphocytic leukemia: insights from bimodal CD49d cases

E. Tissino1, N. Calonaci2, F. Pozzo1, L. Terzi Di Bergamo3, F. Vit1, A. Stacchetti1, R. Bergamin2, T. Bittolo1, R. Papotti1, A. Gaglio1, S. Cozzini4, M.I. Del Principe5, A. Chiarenza6, J. Olivieri7, F. Zaja8, D. Rossi3, R. Bomben1, V. Gattei1, G. Caravagna2, A. Zucchetto1 | 1Clinical and Experimental Onco-Hematology Unit, Centro Di Riferimento Oncologico di Aviano, CRO, IRCCS; 2Cancer Data Science Laboratory, University of Trieste; 3Institute of Oncology Research, Oncology Institute of Southern Switzerland; 4Research and Technology Institute, Area Science Park; 5Ematologia, Dipartimento di Biomedicina e Prevenzione, Università degli studi di Roma Tor Vergata; 6Divisione di Ematologia, Ospedale Ferrarotto, A. O. U. Policlinico-OVE, Università di Catania; 7Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi" DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia; 8Department of Medical, Surgical and Health Sciences, University of Trieste.

CO13 | Dissection of biallelic NOTCH1 disruption in chronic lymphocytic leukemia reveals chromosome 9 copy neutral-loss of heterozygosity

G. Ianna1, F.M. Rossi1, F. Vit1, E. Tissino1, T. Bittolo1, R. Papotti1, A. Gaglio1, M. Ballerini2, F. Zaja2, L. Laurenti3, J. Olivieri4, A. Chiarenza5, R. Laureana6, F. Esposito6, M. Postorino6, M.I. Del Principe6, A. Zucchetto1, R. Bomben1, V. Gattei1, F. Pozzo1. | 1Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano, CRO, IRCCS; 2Department of Medical, Surgical and Health Sciences, University of Trieste; 3Istituto di Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS; 4Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi" DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia; 5Divisione di Ematologia, Ospedale Ferrarotto, A. O. U. Policlinico-OVE, Università di Catania; 6Ematologia, Dipartimento di Biomedicina e Prevenzione, Università degli studi di Roma Tor Vergata

CO14 | A combined immunophenotypic and molecular approach to differentiate T-CUS, low-count T-LGLL and T-LGLL

E. Buson1|2, V. Trimarco1, L. Massarotti1, G. Calabretto1|2, E. Rampazzo1|2, R. Crivellari1|2, G. Pertile1|2, M. Facco1, L. Trentin1, G. Semenzato2, A. Teramo1|2, R. Zambello1|2. | 1Department of Medicine, Hematology division, University of Padova; 2Veneto Institute of Molecular Medicine - VIMM, Italy.

CO15 | Optical genome mapping identifies multiple structural variation and catastrophic rearrangements in B-cell prolymphocytic leukemia

R. Maffei1, A. Paolini1, B. Conte2, L. Bonamici2, S. Giorgi2, S. Martinelli1, F. Giacobbi1, G. Corradini1, F. Pilato1, G. Debbia2, C.G. Atene2, S. Cordella2, A. Cassanelli2, F. Cretì2, M. Morselli2, L. Potenza2, D. Giusti2, E. Colaci2, F. Bettelli2, P. Bresciani2, A. Cuoghi2, A. Gilioli2, A. Messerotti2, V. Pioli2, M. Maccaferri2, G. Leonardi2, F. Forghieri2, M. Luppi2, R. Marasca2, E. Tagliafico1 | 1Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, Azienda Ospedaliero-Universitaria, Policlinico; 2Hematology Unit, and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Italy.

CO16 | Clinical and biological impact of plasma cytokine levels in newly diagnosed chronic lymphocytic leukemia

S. Mouhssine1, C. Cosentino1, M. Almasri1, N. Maher1, J. Nabki1, L. Cividini1, B. Al Deeban1, F. Maiellaro1, R. Dondolin1, M. Bellia1, E. Secomandi1, V. Caneparo2, A. Mahmoud1, C. Deambrogi1, S. Kogila1, J. Ghanej1, S. Rasi1, G. Gaidano1, R. Moia1 | 1Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale; 2Center for Translational Research on Autoimmune & Allergic Diseases – CAAD, Università del Piemonte Orientale, Italy.

CO18 | A novel anti-CD138 antibody AT801 to effectively deliver chitosan NBs for targeting of multiple myeloma and reverting tumor microenvironmental invasiveness

C. Tangredi1|2, M. Argenziano3, D. Busato1, S. Capolla1, A. Zucchetto4, V. Gattei4, R. Cavalli3, P. Macor2, G. Toffoli1, M. Dal Bo1 | 1Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano - CRO, IRCCS; 2Department of Life Science, University of Trieste; 3Deparment of drug science and technology, University of Turin; 4Clinical and Experimental Onco-Hematology, Centro di Riferimento Oncologico di Aviano, IRCCS, Italy.

CO01 | A novel highly recurrent fusion circRNA from the kmt2a::aff1 fusion gene impacting mitochondrial metabolism in B-ALL with the t(4;11)(q21.3-q22.1;q23.3) translocation

D. Tolomeo1, M. Bardini2, S. Venuto1, G. Visci1, A. Lonoce1, L. Calamo1, I. Cifola3, M. Severgnini3, M. Mastrodonato1, D. Semeraro1, L. Valsecchi2, M. Mauri4, R. La Starza5, M. Lucarelli5, A. Azzariti6, S. Serrati6, A. Ferrari7, G. Martinelli8, N. Santoro9, M. Fumagalli2, G. Cazzaniga2|10, G. Fazio2|10, C.T. Storlazzi1. | 1Department of Biosciences, Biotechnologies, and Environment, University of Bari Aldo Moro; 2Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori; 3Institute for Biomedical Technologies ITB, National Research Council CNR; 4School of Medicine and Surgery, University of Milano-Bicocca; 5Hematology and Bone Marrow Transplantation Section, Department of Medicine and Surgery, University of Perugia, Centro di Ricerche EmatoOncologiche, Azienda di Perugia; 6IRCCS Istituto Tumori "Giovanni Paolo II"; 7Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori - IRST "Dino Amadori"; 8Department of Hematology and Oncology Sciences, Institute of Haematology "L. and A. Seràgnoli", S. Orsola University Hospital; 9Pediatric Oncology AOUC of Policlinico of Bari; 10School of Medicine and Surgery, University of Milano-Bicocca

CO21 | Integrated multiomic immune profiling defines the biological basis of minimal residual disease persistence in multiple myeloma

A.M. Corsale1, M. Speciale2, C. Aquilina1, E. Gigliotta1, A. Rizzuto1, M. Biondo3, E. Tofacchi1, A. Romano1, M. Di Simone1, A. Gallo4, N. Caccamo5, F. Dieli5, S. Meraviglia5, S. Siragusa1, C. Botta1 | 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo; 2Department of Surgical, Oncological and Stomatological Disciplines, DICHIRONS, University of Palermo; 3Department of General Surgery and Medical-Surgical Specialties, Hematology Section, University of Catania; 4Department of Research, IRCCS-ISMETT, Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione; 5Department of Biomedicine, Neuroscience and Advanced Diagnosis, Bi. N. D. , University of Palermo

CO23 | Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease

V. Desantis1, A. Andriano1, G. De Martino1, T. Düking2, O. Hartwig2, G. Ingravallo3, M. Biondo4, C. Botta5, R. Ria6, A. Vacca6, A. G. Solimando6 | 1Department of Precision and Regenerative Medicine and Ionian Area-DiMePRe-J, Section of Pharmacology, University of Bari Aldo Moro Medical School; 2Miltenyi Biotec B. V. & Co. KG; 3Pathological Anatomy Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro; 4Department of General Surgery and Medical-Surgical Specialties, University of Catania; 5Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo; 6Internal Medicine Guido Baccelli, University of Bari Aldo Moro Medical School, Italy.

CO25 | P53 isoform diversity in multiple myeloma: unexplored risk factor beyond TP53 mutation and del(17p)

E. Borsi1, A. Vitale2, V. Solli2, V. Meixian Vuong2, M. Martello2, I. Vigliotta1, A. Poletti2, S. Armuzzi2, B. Taurisano2, A. Varacalli1|2, G. Mazzocchetti2, A. Croce2, I. Pistis1, E. Zamagni1|2, P. Tacchetti1, I. Rizzello1|2, C. Terragna1 | 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 2DIMEC – Dipartimento di Medicina e Chirurgia, Università di Bologna, Italy.

CO26 | From precursor diseases to multiple myeloma: remodeling of the osteoblastic niche at single cell resolution

M. Dessena1, F. Mohammadi1, T. Torelli2, C. Manferdini3, C. Sitzia1, A. Guidi2, R. Vescovini1, M. Scita4, M. Bernardi4, D. Toscani4, A. Poletti1, N.T. Iannozzi1, V. Raimondi1, O. Lungu1, S. Ricci4, G. Todaro4, G. Sammarelli4, A. B. Dalla Palma4, G. Lisignoli3, L. Agnelli2, N. Giuliani1|4, P. Storti1 | 1Dipartimento di Medicina e Chirurgia, Università di Parma; 2Dipartimento di Diagnostica Innovativa, IRCCS Istituto Nazionale dei Tumori; 3Laboratorio di Immunoreumatologia e Rigenerazione Tissutale, IRCCS Istituto Ortopedico Rizzoli; 4U. O. Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma Programma Dipartimentale Mieloma Multiplo e Gammopatie Monoclonali

CO27 | Targeting glutamine metabolism potentiates T cell engager–mediated immunotherapy in multiple myeloma

V. Raimondi1, D. Toscani1|2, R. Vescovini1, O. Lungu1, M. Dessena1, C. Sitzia1, N.T. Iannozzi1, B. Dalla Palma2, M. Scita2, S. Ricci1, P. Storti1, N. Giuliani1|2 | 1Laboratory of Hematology, Department of Medicine and Surgery, University of Parma; 2Hematology, “Azienda Ospedaliero-Universitaria di Parma”

CO28 | NONO shapes multiple myeloma progression through paraspeckle-dependent and independent pathways

E. Taiana1, V. Traini2, A. Devecchi3, I. Silvestris2, G. Fabbiano1, N. Puccio4, I. Craparotta5, M. Bolis5|6, R. Piva7, A. Neri8, L. Agnelli3|9, F. Passamonti1|2, N. Bolli1|2, D. Ronchetti2 | 1Hematology, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico; 2Department of Oncology and Hemato-Oncology, University of Milan; 3Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori; 4Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia; 5Oncology Department, Computational Oncology Unit, Mario Negri IRCCS; 6Bioinformatics Core Unit, Institute of Oncology Research - IOR; 7Department of Molecular Biotechnology and Health Sciences, University of Turin; 8Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia; 9Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Italy.

CO32 | ARQ531 targets MAPK–S6K1 signaling and synergizes with lenalidomide in RAS-mutant and wild-type multiple myeloma

D. Soncini1|2, P. Becherini D.2, E. Gelli3, M. Chen4, A. Carreira5, Provenzani A.5, F. Ladisa2, M. Squillario1, I. Traverso2, G. Giorgetti1, M. Garibotto1, F. Guolo1|2, M. Piana1, R.M. Lemoli1|2, M. Cea1|2 | 1IRCCS Ospedale Policlinico San Martino; 2Clinic of Hematology, Department of Internal Medicine and Medical Specialties DiMI, University of Genoa; 3Genetics and Epigenetics of Behavior Laboratory, Fondazione Istituto Italiano di Tecnologia IIT; 4Harvard University; 5University of Trento, Department of Cellular, Computational and Integrative Biology CIBIO. .

CO34 | Developing a scalable model for genetic analysis of extra-myeloid tissues to resolve somatic-germline ambiguity in myeloid disorders

N. Lelli1, E. Ricci1, G. Silvestrini1, E. Fabiani1, E. Marchionni2, G. Ranucci1, V. Ferradini2, C. Minotti1|2, S. Gastaldi1|2, G. D' Ortenzi1|2, C. Page1, C. Di Raimondo3, P. Ricci1, E. Lumia1|4, E. Santinelli4|5, T. Ottone1, G. Novelli1|2, F. Sangiuolo1|2, C. Gurnari1, E. Attardi1, M.T. Voso1 | 1Department of Biomedicine and Prevention, University of Rome Tor Vergata; 2Medical Genetics Unit, Policlinico Tor Vergata, University of Rome Tor Vergata; 3Dermatology Unit, Policlinico Tor Vergata; 4Department of Biomedicine and Prevention, PhD program in immunology, molecular medicine, and applied biotechnologies, University of Rome Tor Vergata; 5Fondazione Policlinico Universitario Campus Bio-Medico

CO36 | TGF-β pathway deregulation in SF3B1-mutated low risk myelodysplastic syndrome patients

E. Lumia1, E. Fabiani2|3, P. Bielli2, M. Sarchi4, M. Senatore2, C. Fiducioso4, H. Hajrullaj2, C. Iannini4, M. Rasicci2, G. Silvestrini2, N. Lelli1, A. Onorato2, A. Cristiano1|5, M. Pieraccioli6|7, F. Mallegni2, F. Moretti2, L. Guarnera1, G. Falconi2, S. Hutter8, N. Nadarajah8, T. Haferlach8, L. Malcovati4|9, C. Sette2, M.T. Voso2 | 1Department of Biomedicine and Prevention, PhD program in immunology, molecular medicine and applied biotechology, University of Tor Vergata; 2Department of Biomedicine and Prevention, University of Tor Vergata; 3UniCamillus-Saint Camillus International University of Health Sciences; 4Department of Molecular Medicine, University of Pavia; 5Operative Research Unit of Laboratory, Fondazione Policlinico Universitario Campus Bio-Medico; 6Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Hearth; 7GSTEP-Organoids Core Facility, Fondazione Policlinico Agostino Gemelli IRCCS; 8MLL Munich Leukemia Laboratory; 9Department of Hematology, Fondazione IRCCS Policlinico S. Matteo.

CO40 | DNA methylation signatures are associated with clinical response to azacitidine in high-risk myelodysplastic syndrome patients

E. Lumia1, A.G. Lema Fernandez2, E. Fabiani3|4, C. Nardelli2, G. Falconi3, E. Galossi3, H. Hajrullaj3, M. Crocioni2, M. Quintini2, A. Cristiano1|5, P. Niscola6, M.P. Martelli2, R. La Tagliata7, C. Mecucci2, M.T. Voso3 | 1Department of Biomedicine and Prevention, PhD program in immunology, molecular medicine and applied biotechology, University of Tor Vergata; 2Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital; 3Department of Biomedicine and Prevention, University of Tor Vergata; 4UniCamillus-Saint Camillus International University of Health Sciences; 5Operative Research Unit of Laboratory, Fondazione Policlinico Universitario Campus Bio-Medico; 6Division of Haematology, Sant' Eugenio Hospital; 7Hematology, Belcolle Hospital, Italy.

SIES: Posters

94

P002 | Multi-omics analysis unravels new biomarkers of relapse risk in adult Philadelphia-positive B-ALL

R. Merlo1|2, D. Cardinali3, F. Kaiser3, A. Caregari1|2, S. Orsi1|2, E. Roncaglia1|2, S.H. Anjedani4, M. Beldinanzi3, S. Bresolin4, E. Gaffo1, S. Chiaretti3, S. Bortoluzzi1 | 1Computational Genomics Group, Department of Oncology, Surgery and Gastroenterology, University of Padua; 2Department of Biology, University of Padua; 3Department of Translational and Precision Medicine, University of Roma "La Sapienza"; 4Pediatric hematology, oncology and hematopoietic cell & gene therapy, Pediatric Research Institute, Città della Speranza

P003 | Long-read RNA sequencing for investigating bortezomib resistance mechanisms in multiple myeloma cell lines

G.N. Conti1, E. La Spina1, L. Longhitano1, J Ferrigno1, S. Giallongo2, A. Duminuco3, G.A. Palumbo3, I. Dulcamare4, C. Conticello5, S. Forte6, S.P. Lombardo1, G. Chisari6, D. Cambria4 , D. Calvo1, M.E. Gallo Cantafio5, G. Li Volti1, N. Amodio5, F. Di Raimondo4, A. Romano4, C. Giallongo1, D. Tibullo1 | 1Department of Biomedical and Biotechnological Sciences, University of Catania; 2Faculty of Medicine and Surgery, University of Enna “Kore”; 3Department of Medical and Surgical Sciences and Advanced Technologies “G. F. Ingrassia”, University of Catania; 4Department of General Surgery and Medical-Surgical Specialties- University of Catania, Division of Haematology; 5Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro; 6Mediterranean Institute of Oncology.

P004 | Genomic and functional characterization of the murine acute myeloid leukemia cell line c1498 as a preclinical model of venetoclax/azacitidine resistance

M. Ghetti1, I. De Santis2, D. Tolomeo3, F. Ruggieri1|4, C. Bracci1, M.T. Bochicchio1, M. Paganelli1, A. Ferrari1, S. Sangaletti5, C. T. Storlazzi3, G. Simonetti1 | 1Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST "Dino Amadori"; 2Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST "Dino Amadori"; 3Department of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro; 4Department of Medical and Surgical Sciences DIMEC, University of Bologna; 5Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori

P005 | ASXL1 variant allele frequency as a modulator of genetic heterogeneity in myelofibrosis

G. Iaquinta1, M. Breccia2, P. Chiusolo3, A. Laganà2, M. Santopietro4, M. Ragazzo1, C. Cerroni1, E. Rossi3, A. Tamburini5, S. Crescenzi Leonetti5, M. Rossi3, C. Tatarelli6, E. Abruzzese7, M. Trawinska7, R. Latagliata8, A. Andriani9, L. Maurillo10, L. Guarnera10, K. Paciaroni11, P. Cercola12, G. Pessina12, V. De Stefano3, P. Grammatico1 | 1Medical Genetics Experimental Medicine Department Sapienza University San Camillo-Forlanini Hospital; 2Hematology Department of Translational and Precision Medicine Policlinico Umberto I Sapienza University; 3Institute of Hematology Catholic University; 4Hematology Department San Camillo-Forlanini Hospital; 5Hematology Department San Giovanni Hospital; 6Unit of Hematology Sapienza University Sant'Andrea Hospital; 7Sant'Eugenio Hospital Tor Vergata University; 8Hematology Department Belcolle Hospital; 9Hematology Department Nuovo Regina Margherita Hospital; 10Hematology Department AOU Policlinico Tor Vergata; 11Hematology Department Santo Spirito Hospital; 12Laboratory of Medical Genetics Santa Rosa Hospital.

P006 | The IL8-CXCR1/CXCR2 axis plays a role in the mobilization process of polymorphonuclear myeloid-derived suppressor cells in patients with primary myelofibrosis

R. Campanelli1, S. Mantovani2, A. La Gaipa2, C. Ramirez3, C. Abbà4, A. Carolei1, P. Catarsi1, C. Del Fante5, G. Barosi1, M. Massa4, V. Rosti1 | 1Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia; 2Department of Translational and Clinical Research, Laboratory of Clinical Immunology, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia; 3Laboratory of RNA and Disease Data Science, Department of Cellular, Computational and Integrative Biology, University of Trento, Trento; 4General Medicine 2-Center for Systemic Amyloidosis and High-Complexity Disease, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia; 5Division of Immunohaematology and Transfusion Service, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia.

P007 | Pre-clinical efficacy of a novel combined pharmacological approach targeting JAK and ERK in a myelofibrosis mouse model

M. Bertesi1|3, L. Tavernari1|2, A. Neroni1|3, E. Papa1|3, S. Rontauroli1|2, E. Bianchi1|3, M. Mirabile1|2, R. Norfo1|2, S. Parenti1|2, C. Tombari1|2, C. Carretta1|2, M. Malerba1|3, L. Fabbiani4, P. Guglielmelli5|6, L. Losi4, E. Tagliafico7|8, A. M. Vannucchi5|6, R. Manfredini1|2 | 1Interdepartmental Centre for Stem Cells and Regenerative Medicine, University of Modena and Reggio Emilia; 2Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia; 3Department of Life Sciences, University of Modena and Reggio Emilia; 4Pathology Unit , Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia; 5CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi; 6Department of Experimental and Clinical Medicine, University of Florence; 7Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia; 8Department of Laboratory Medicine, Diagnostic Hematology and Clinical Genomics Unit, Modena University Hospital

P008 | JAK2E837K: a novel mutation post-polycythemia vera myelofibrosis

G. Pasqualini1|7, M. Giovannini2, E. De Marinis3|4, M. Gallo5, P. Niscola2, A. Zaza1|3, E. E. Barroso1, M. Gentile3, G. Catalano1|6, C. Nervi3, N.I. Noguera1|6 | 1IRCCS Santa Lucia Foundation; 2Hematology Unit, S. Eugenio Hospital ASL Roma 2; 3Department of Medical and Surgical Sciences and Biotechnologies, University of Rome La Sapienza; 4Department of Health and Life Sciences, European University of Rome; 5Department of Medicine and Surgery, University of Parma; 6Department of Biomedicine and Prevention, Tor Vergata University; 7Department of Biology and Biotechnology "Charles Darwin", University of Rome La Sapienza, Italy.

P009 | Beyond the Dynamic International Prognostic Scoring System: the role of inflammation in myelofibrosis

A. Votto1, A. Duminuco2, A. Brunetti1, L. Sijoni1, G. Lavenia3, G.A. Palumbo4, S. Galimberti1 | 1UO di Ematologia, AOU Pisana, Ospedale Santa Chiara; 2UO di Ematologia, AOU Policlinico “G. Rodolico”- San Marco; 3Scuola di Specializzazione in Ematologia - Università degli Studi di Catania; 4Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G. F. Ingrassia”, Università degli studi di Catania

P010 | Next generation sequencing in triple negative essential thrombocythemia: impact of additional mutations in risk assessment

L. Tosoni1, E. Toffoletti1|2, T. Liani2, S. Di Giusto1, G. Morelli1, M. Bergnach1, M. Moro1, C. Cozzarolo1, D. Damiani1|2, R. Fanin1|2, E. Toffoletti1|2, M. Tiribelli1|2 | 1Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Friuli Centrale; 2Department of Medicine - DMED, University of Udine

P011 | Metabolic rewiring fuels immunosuppression and fibrosis in myelofibrosis via the lactate–glutamate axis

G.A. Palumbo1, C. Giallongo2, S. Giallongo3, E. La Spina1, L. Longhitano1, A. Duminuco1, J. Ferrigno2, N. Conti2, G. Li Volti2, F. Bellia2, A.M. Amorini2, D. Calvo2, A. Romano4, R. Caltabiano1, G. Broggi1, S. Lombardo2, F. Di Raimondo4, D. Tibullo2 | 1Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G. F. Ingrassia", Università degli Studi di Catania; 2Dipartimento di Scienze Biomediche e Biotecnologiche, Università degli Studi di Catania; 3Facoltà di Medicina e Chirurgia, Università di Enna "Kore"; 4Dipartimento di Chirurgia Generale e Specialità Medico-Chirurgiche, Università degli Studi di Catania

P014 | Azacitidine remodels hematopoietic stem/progenitor cell fate and restores erythroid differentiation in myelodysplastic/myeloproliferative neoplasms with neutrophilia via reactivation of the GATA switch

S. Spinelli1, F. Duca1|2, D. D’aliberti1, F. Colombo1|2, E. Agostani1|2, A. Zappaterra1|2, S. Pierini1|2, M. B. Ferrari1|2, G. Cotilli1|2, V. Rago1|2, A. Rapella1|2, I. Crespiatico1, D. Fontana1, M. Pelateo1, A. Sessa3, C. Barone1, F. Bonacina1, E. Azzoni1|4, A. Aroldi1|2, E. Elli2, L. Mologni1, C. Gambacorti-Passerini1|2, R. Piazza1|2 | 1Department of Medicine and Surgery, University of Milano-Bicocca; 2Ematologia, Fondazione IRCCS San Gerardo dei Tintori; 3Neuroepigenetics Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute; 4Fondazione IRCCS San Gerardo dei Tintori, Italy.

P017 | The uncoupled NRF2-HMOX1 axis and persistent oxidative stress in myelofibrosis neutrophils, beyond JAK blockade

E. La Spina1, C. Giallongo1, L. Longhitano1, S. Giallongo2, A. Duminuco3, G. N. Conti1, D. Calvo1, J. Ferrigno1, A.M. Amorini1, G. Li Volti1, A. Santisi3, A. Romano4|5, F. Di Raimondo4|5, A. Lucchesi6, G.A. Palumbo3, D. Tibullo1 | 1Department of Biotechnological and Biomedical Sciences, University of Catania; 2Department of Medicine and Surgery, University of Enna “Kore”; 3Department of Medical, Surgical Sciences and Advanced Technologies G. F. Ingrassia, University of Catania; 4Department of General Surgery and Medical-Surgical Specialties, University of Catania; 5Division of Hematology, Azienda Policlinico, University of Catania; 6Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST, Italy.

P018 | Improving diagnostic standardization in myeloproliferative neoplasms: results from the Italian JakNet Program

F. Gesullo1, E. Nacca1, G. Rotunno1, F. Vanderwert1, R. Cucci2, G. Polese2, S. Soverini3, T. Barbui4, V. De Stefano5, U. Gianelli6, F. Pane7, Ga. Palumbo8, F. Passamonti9, Mt. Voso10, A. Piciocchi2, P. Fazi2, M. Vignetti2, Am. Vannucchi1, P. Guglielmelli1 | ¹Department of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative CRIMM, AOU Careggi, University of Florence; ²GIMEMA Foundation; ³Department of Medical and Surgical Sciences DIMEC, Institute of Hematology "Lorenzo e Ariosto Seràgnoli", University of Bologna; ⁴Fondazione per la Ricerca Ospedale di Bergamo FROM Ente del Terzo Settore ETS; ⁵Section of Hematology, Catholic University, Fondazione Policlinico Gemelli IRCCS; ⁶Pathology Unit, Department of Health Sciences, University of Milan and Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo; ⁷Università degli Studi di Napoli Federico II; ⁸Department of Medical, Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Università degli Studi di Catania; ⁹Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan; ¹⁰Department of Biomedicine and Prevention, Tor Vergata University

P022 | Fourier-transform infrared spectroscopy analysis of plasma-derived extracellular vesicles as a tool to detect TKI-related toxicity in chronic myeloid leukemia patients: a preliminary study

S. Mutti1|2, A. Cavalleri1|2, A. Sicuranza3, A. Leoni 1|2, F. Trenta1|2, L. Garuffo1|2, B. Xhahysa1|2, F. Re1|2, M. Bocchia3, M. Farina 2, M. Malagola1|2, D. Russo1|2, S. Bernardi1|2. | 1University of Brescia, Department of Clinical and Experimental Sciences; 2ASST Spedali Civili di Brescia, Unit of Blood Diseases and Bone Marrow Transplant; 3Hematology Unit, Department of Medicine, Surgery and Neuroscience, Azienda Ospedaliera Universitaria Senese, University of Siena, Italy.

P023 | SETD2 loss in chronic myeloid leukemia promotes metabolic reprogramming and genomic instability leading to therapeutic resistance and disease progression

M. Mancini1|2, L. Romagnoli2, S. De Santis2, S. Bruno2, A. Tagliavia2, C. Mosca2, A. Oldani1, A. Merlotti3, D. Remondini3, E. Esposito4, J. Fiori4, F. Castagnetti1|2, M. Iezza2, R. Restuccia2, M. Lasala2, A. Iurlo5, M Cerrano6, S. Galimberti7, P. L. Zinzani1|2, S. Soverini1 | 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 2Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna; 3Department of Physics and Astronomy "DIFA", Università di Bologna; 4Dipartimento di Chimica "Giacomo Ciamician", Università di Bologna; 5UO Onco-ematologia, Fondazione IRCCS Ca' Granda - Ospedale Policlinico; 6A. O. U. Citta della Salute e della Scienza di Torino; 7Clinical and Experimental Medicine, Hematology, University of Pisa. .

P024 | Inflammatory and epigenetic mechanisms driving chronic myeloid leukemia: advances from the ‘Stem CML Cure’ project

C. Bono1|2, F. Guerrini1, A. Votto1 , A. Brunetti1, I. Santo1, L. Sijoni1, L. Trombello1, A. Sicuranza3, M. Bocchia3|4, S. Galimberti1|2 | 1Università di Pisa, 2Azienda Ospedaliera Universitaria Pisana, 3Università di Siena, 4Azienda Ospedaliero-universitaria Senese

P025 | PD-L1 expression on PB CD26+ LSCs on chronic myeloid leukemia patients at diagnosis: role and implications

E. Pacini1, A. Sicuranza1, P. Pacelli1, S. Galimberti2, C. Bono2, F. Guerrini2, E. Abruzzese3, M. Crugnola4, V. Giai5, C. Fava6, I. Capodanno7, F. Sorà8, D. Cattaneo9, A. Iurlo9, F. Muriano10, E. Bestoso1, G. Beffa1, K. Peccia1, M. Bocchia1, D. Raspadori1 | 1Hematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena; 2Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa; 3Sant'Eugenio Hospital, Tor Vergata University; 4Ematologia e Centro BMT, Azienda Ospedaliero-Universitaria di Parma; 5Division of Hematology, Città Della Salute e Della Scienza, Turin; 6A. O. Ordine Mauriziano di Torino, Turin; 7SOC Ematologia Azienda USL-IRCSS di Reggio Emilia, Reggio Emilia; 8Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore; 9Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico; 10Hematology - Department of Clinical Medicine and Surgery, Federico II University, Naples

P026 | Tracking residual chronic myeloid leukemia: complementary insights from CD26⁺ stem cells and extracellular BCR::ABL1

A. Cavalleri 1|2, S. Mutti 1|2, A. Sicuranza 3, P. Pacelli 3, A. Leoni 1|2, C. Ielo 4, L. Paolini 5, V. Mangolini 6|7, T. Miracapillo 3, C. Turriziani 3, E. Abruzzese 8, M. Farina 1, A. Radeghieri 6, M. Malagola 1, M. Breccia 4, M. Bocchia 3, D. Russo 1, S. Bernardi 1|2|9 | 1Department of Clinical and Experimental Sciences, Università di Brescia - Unit of Blood Diseases and Bone Marrow Transplant, ASST Spedali Civili; 2Centro di Ricerca Emato-Oncologica AIL, CREA, ASST Spedali Civili; 3University of Siena, Azienda Ospedaliera Universitaria; 4Umberto I Policlinico, La Sapienza University; 5Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Università di Brescia; 6Department of Molecular and Translational Medicine, Università di Brescia; 7IRCCS Fondazione Don Carlo Gnocchi ONLUS; 8Hematology, S. Eugenio Hospital, ASLRoma2; 9National Center for Gene Therapy and Drugs based on RNA Technology

P027 | Spalt-like transcription factor 4 deregulation in low risk myelodysplastic syndrome SF3B1-mutated patients

E. Lumia1, E. Fabiani2|3, H. Hajrullaj2, S. Bianculli2, E. Ricci2, A. Cristiano1|4, L. Guarnera1, G. Falconi2, M.T. Voso2 | 1Department of Biomedicine and Prevention, PhD program in immunology, molecular medicine and applied biotechology, University of Tor Vergata; 2Department of Biomedicine and Prevention, University of Tor Vergata; 3UniCamillus-Saint Camillus International University of Health Sciences; 4Operative Research Unit of Laboratory, Fondazione Policlinico Universitario Campus Bio-Medico.

P029 | Sex-based differential DNA methylation signatures in myelodysplastic neoplasms

S. De Pourcq1, G. Mattiuz1, E. Celoni1, M. Raddi1|2, G. andreossi1, C. Amato1, B. Caciagli1, L. Rigodanza1, A. Consagra1, V. Santini1 | 1MDS Unit, Hematology, AOU Careggi, University of Florence, Department of Experimental and Clinical Medicine; 2University of Siena, Department of Medical Biotechnologies, Siena

P030 | Imetelstat restores erythroid maturation in responding low risk myelodysplastic disorders patients

M.G. Raddi1|2, S. Bencini3, G. Mattiuz1, S. Depourcq1, A. Consagra1, L. Rigodanza4, G. andreossi4, F. Annunziato3|5, V. Santini1|4 | 1MDS Unit, Hematology, DMSC, University of Florence; 2Department of Medical Biotechnologies, University of Siena; 3Flow Cytometric and Immunotherapeutic Diagnostic Center, AOU Careggi; 4Azienda Ospedaliero-Universitaria Careggi, Hematology department University of Florence; 5Department of Experimental and Clinical Medicine, University of Florence, Italy.

P031 | From haematological disorders to immune dysregulation: the role of extended immunophenotyping to guide the diagnosis towards inborn errors of immunity

B. Borsellino1|2, G. Colafranceschi3, M. Irno Consalvo3, M. Sgrulletti4, E. Del Duca4, E. Ricci3, N. Lelli3, A. Catapano3, V. Serafini3, S. Di Cesare5, G. Di Matteo6, C. Gurnari3, C. Cancrini5|6, F. Buccisano3, M.T. Voso3, V. Moschese4, E. Attardi3 | 1Department of Biomedicine and Prevention, PhD program in immunology, molecular medicine, and applied biotechnologies, University of Rome Tor Vergata; 2Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città; della Salute e della Scienza”; 3Department of Biomedicine and Prevention, University of Rome Tor Vergata; 4Pediatric Immunopathology and Allergology Unit, Policlinico Tor Vergata, University of Rome Tor; Vergata; 5Unit of Clinical Immunology and Vaccinology, IRCCS Bambino Gesù Children Hospital; 6Department of Systems Medicine, Tor Vergata University.

P035 | Venetoclax shows robust and subtype dependent preclinical activity in acute lymphoblastic leukemia models characterized by BCL2 dependence

F. Lo Schiavo 1, G. Martinelli 2, C. Salvesi 1, L. Ledda 1, A. Spedaluzzi 1, E. Fonzi 3, A. Ghelli Luserna Di Rorà 4, C. Papayannidis 5, P. Salutari 6, M. Rondoni 7, G. Marconi 8, A.M. Mianulli 9, M. B. Giannini 10, F. Giglio 11, C. Pasciolla 12, M. Fumagalli 13, A. Imovilli 14, E. Mauro 15, S. Galimberti 16, G. Simonetti 1, A. Ferrari 1 | 1Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST "Dino Amadori"; 2University of Bologna, Istituto di Ematologia “Seràgnoli”; 3Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST "Dino Amadori"; 4Fondazione Pisana per Scienza ONLUS; 5IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 6Dipartimento Oncologia Ematologia, Ospedale Civile Santo Spirito; 7Hematology Unit, Ospedale S. Maria delle Croci; 8Hematology Unit, University of Bologna, S. Maria delle Croci Hospital; 9Hematology Infermi Hospital; 10Hematoloy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST "Dino Amadori"; 11Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute; 12Hematology and Bone Marrow Transplantation Unit, Istituto Oncologico IRCCS "Giovanni Paolo II"; 13Hematology Unit, Ospedale San Gerardo; 14Hematology Azienda USL-IRCCS Reggio Emilia; 15UOC Ematologia Ospedale Ca' Foncello Azienda ULSS 2 Marca Trevigiana; 16Hematology Unit AOUP Santa Chiara

P036 | Germline and somatic cohesin genes alterations in pediatric acute lymphoblastic leukemia

D. Gaspari1, S. Rebellato1, L. Rigotti2, A. Lettieri3, S. Castiglioni3, C. Saitta1, Lr. Bettini1, D. Silvestri1, M. Mariani4, S. Totaro3, O. Spinelli5, A. Pastorczak6, D. Brandes7, U. Fischer4, A. Borkhardt4, S. Strehl8, L. Lo Nigro9, B. Buldini10, J. Hauer11, F. Auer11, L. Kester12, R. Kuiper12|13, L. Vinti14, F. Locatelli14|15, C. Gervasini3|17, V. Massa3|17, A. Selicorni4, G. Fazio1, G. Cazzaniga1|16 | 1Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori;2Dep. of Paediatrics, V. Buzzi Children's Hospital, University of Milan; 3Dep. of Health Sciences, University of Milan; 4UOC Paediatrics, Centro Fondazione Mariani per il Bambino Fragile, ASST Lariana; 5Hematology and bone Marrow Transplant Unit, ASST-Papa Giovanni XXIII Hospital; 6Department of Pediatrics, Oncology and Hematology, Medical University of Lodz; 7Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf; 8St. Anna Children’s Cancer Research Institute; 9Cytogenetic-Cytofluorimetric-Molecular Biology Laboratory Center of Pediatric Hematology Oncology, Azienda Policlinico "G. Rodolico"; 10Department of Pediatric Hematology and Oncology, University-Hospital of Padova; 11Technical University of Munich, School of Medicine, Department of Pediatrics; 12Princess Maxima Center for Pediatric Oncology; 13Department of Genetics, Utrecht University Medical Center; 14IRCCS Ospedale Pediatrico Bambino Gesù; 15Catholic University of the Sacred Heart; 16Medical Genetics, Università di Milano Bicocca; 17“Aldo Ravelli” Center for Neurotechnology and Experimental Brain Therapeutics, University of Milan

P038 | Targeted digital analysis provides high-resolution, clinically-relevant copy number alterations and enables the identification of high-risk lesions already known in adult acute lymphoblastic leukemia

C. Salvesi1, G. Martinelli2, F. Lo Schiavo1, M. Paganelli1, A. Spedaluzzi1, L. Ledda1, C. Papayannidis3, G. Marconi4, M. Rondoni5, A.M. Mianulli6, B. Giannini7, C. Pasciolla8, F. Giglio9, S. Galimberti10, M. Fumagalli11, P. Salutari12, C. Terragna13, M.B. Giannini14, G. Montalban15, L. Atanesyan15, S. Savola15, G. Simonetti1, A. Ferrari1 | 1Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST "Dino Amadori"; 2University of Bologna, Istituto di Ematologia “Seràgnoli”; 3IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 4Hematology Unit, University of Bologna, S. Maria delle Croci Hospital; 5Hematology Unit & Romagna Transplant Network, S. Maria delle Croci hospital; 6Hematology, Infermi Hospital; 7Laboratorio Unico- AUSL della Romagna Pievesestina di Cesena; 8Hematology and Bone Marrow Transplantation Unit, Istituto Oncologico IRCCS “Giovanni Paolo II”; 9Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute; 10Hematology Unit, AOUP Santa Chiara; 11Hematology Unit, Ospedale San Gerardo; 12Dipartimento Oncologia Ematologia, Ospedale Civile Santo Spirito; 13IRCCS - Azienda Ospedaliero Universitaria di Bologna Laboratorio di Biologia Molecolare - Istituto di Ematologia "Seràgnoli"; 14Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori IRST "Dino Amadori"; 15MRC Holland Company

P039 | Targeting oncogene-induced senescence in ETV6::RUNX1 pre-leukemic cells

D. Acunzo1, M. Bertagna1, G. Risca2, L. Beneforti1, S. Bresolin3|4, S. Galimberti2|5, I. Sánchez-García6|7, A. Biondi1, G. Cazzaniga1|8, C. Palmi1 | 1Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori; 2Bicocca Bioinformatics, Biostatistics and Bioimaging Centre B4, School of Medicine and Surgery, University of Milano-Bicocca; 3Pediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital; 4Onco-Hematology, Stem Cell Transplant and Gene Therapy, Istituto di Ricerca Pediatrica Foundation - Città della Speranza; 5Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori; 6Institute for Biomedical Research of Salamanca IBSAL; 7Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca; 8School of Medicine and Surgery, University of Milano-Bicocca; 9Pediatrics, Fondazione IRCCS San Gerardo dei Tintori.

P040 | Metabolic reprogramming and DNA repair plasticity fuel resistance to long-term CHK1/CHK2 inhibition in B-cell acute lymphoblastic leukemia

A. Marranci1, T. Salvadori1|2, A. Padella3, F. Rea1|2, A. Ferrari4, F. Olimpico1, N. Ndimurwanko1, F. Greco1, E. Fonzi4, C. Baldazzi5, M.C. Fontana4, M. Ghetti4, L. Mcdonnell1, I. Squiccimarro1|6, E. Ottalagana1|6, P. Mastella1|6, G. Martinelli4|5, G. Simonetti4, A. Ghelli Luserna Di Rora'1 | 1Fondazione Pisana per la Scienza Onlus; 2University of Pisa; 3WellMicro srl; 4Istituto Romagnolo per lo studio dei Tumori "Dino Amadori"; 5Dipartimento di Scienze Mediche e Chirurgiche-Università di Bologna; 6NEST laboratory, Scuola Normale Superiore, Italy.

P041 | Acute myeloid leukemia across ages: metabolic rewiring and genomic hotspots in adult and pediatric therapy resistance

C. Banella1, G. Mattei1, S. Travaglini2, M. Ascone1, A. Pasha3, M. Veltroni1, A. Magi3, E. Sieni1, A. Tondo1, N.I. Noguera3|4, M. Calvani1 | 1AOU IRCCS Meyer; 2Università degli Studi di Roma Tor Vergata; 3Università degli Studi di Firenze; 4IRCCS Fondazione Santa Lucia, Italy.

P044 | From cells to vesicles: next-generation measurable residual disease tracking in acute myeloid leukemia with NGS and digital PCR

A. Leoni1|2, M. Farina2, E. Borlenghi3, L. Garuffo1|2, B. Xhahysa1|2, A. Cavalleri1|2, F. Trenta1|2, F. Re1|2, S. Mutti1|2, E. Morello2, D. Avenoso2, D. Russo2, M. Malagola2, S. Bernardi1|2 | 1Centro di Ricerca Emato-Oncologico AIL, ASST Spedali Civili di Brescia; 2Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia; 3Hematology Unit, ASST Spedali Civili di Brescia

P046 | Beyond the mutation: prognostic role of FLT3-ITD length and genomic context in acute myeloid leukemia

A. Leoni1|2, M. Farina2, D. Bertoli3, C. Giupponi3, E. Borlenghi4, B. Xhahysa1|2, L. Garuffo1|2, A. Cavalleri1|2, F. Trenta1|2, F. Re1|2, S. Mutti1|2, D. Avenoso2, D. Russo2, M. Malagola2, R. Bresciani5, G. Biasiotto6|7, S. Bernardi1|2 | 1Centro di Ricerca Emato-oncologico AIL, ASST Spedali Civili di Brescia; 2Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia; 3Department of Clinical Laboratory, ASST Spedali Civili di Brescia; 4Hematology Unit, ASST Spedali Civili di Brescia; 5Division of Biotechnology, Department of Molecular and Translational Medicine, University of Brescia; 6Department of Molecular and Translational Medicine, University of Brescia; 7Highly Specialized Laboratory, ASST Spedali Civili di Brescia

P047 | NGS analysis in acute myeloid leukemia: implications for the identification of predisposing germline variants

B. Giannini1, L. Bagli1, A. Nicoletti1, G. F. Prisinzano1, M.T. Bochicchio1, M. Rondoni2, G. Marconi2, A.M. Mianulli3, F. Monaco3, M.B. Giannini4, M. Norata Marianna4, I. Melandri1, M. Lacchini1, D. Aufiero1, P. Altana1, C. Arlotti1, D. Ciccarelli1, E. Emiliani1, O. Donati1, C. Graziano1 | 1Lab Unico AUSL della Romagna U. O. Genetica Medica; 2U. O. di Ematologia Ravenna AUSL della Romagna; 3U. O. di Ematologia Rimini AUSL della Romagna; 4Hematology Unit; IRCCS - Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" -IRST S.r.l

P048 | Autophagy inhibition potentiates midostaurin efficacy in FLT3-mutated acute myeloid leukemia under hypoxic conditions

C. Mosca1|2, S. Bruno1|2, M. Mancini1|3, D. Forte1, S. De Santis1, L. Romagnoli1, S. Soverini1 | 1DIMEC- Department of Medical and Surgical Science-University of Bologna ; 2Center for Applied Biomedical Research CRBA, University of Bologna; 3IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.

P053 | Acute myeloid leukemia-derived extracellular vesicles induced DNA methylation changes responsible for inflammatory program in normal hematopoietic stem progenitor cells

D. Lamorte1, G. Calice1, S. Trino1, M. Santodirocco2, A. Caivano3, L. De Luca3, I. Laurenzana1 | 1Laboratory of Preclinical and Translational Research, IRCCS Centro di Riferimento Oncologico della Basilicata - CROB; 2Trasfusional Medicine Department, Puglia Cord Blood Bank, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital; 3Unit of Clinical Pathology, IRCCS Centro di Riferimento Oncologico della Basilicata CROB

P054 | Discontinuation of venetoclax-based therapies in molecularly selected patients with acute myeloid leukemia in complete remission

G. Ciolli1, F. Mannelli1|2, M. Frigeni3, M. Piccini1, B. Scappini1, F. Crupi1|2, E. Quinti1, A. Pasquini1, J. Caroprese1, G. Cannetti1, G. Rotunno2, F. Pancani2, L. Signori2, C. Maccari2, P. Guglielmelli1|2, A. Rambaldi3, A.M. Vannucchi1|2 | 1Hematology Department, Azienda Ospedaliero-Universitaria Careggi; 2Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence; 3Hematology & Bone Marrow Transplantation Unit, Azienda Socio-Sanitaria Territoriale ASST Ospedale Papa Giovanni XXIII

P055 | First interim analysis of venetoclax real-world observational study on newly-diagnosed acute myeloid leukemia patients in Italy

E. Todisco1, C. Alati2, E. Audisio3, M. Lunghi4, P. Zappasodi5, A. Curti6, V. Calafiore7, V. Federico8, M. Parisi9, S. Prassede10, M. Breccia11, V. Cardinali12, M. Frigeni13, M. Piccini14, D. Capelli15, N.S. Fracchiolla16, L. Maurillo17, L. Rizzo18, A. Candoni19, E. De Bellis20, S. Vitiello21, A. Di Veroli22, B. Serio23, I. Zacheo24, L. Di Caprio25, P. Finsinger25, G. Gualberti25, B. Neri25, M. Ubezio26 | 1SC Hematology, "Busto Arsizio" Hospital, ASST Valle Olona; 2U. O. C. of Haematology, Grande Ospedale Metropolitano Bianchi Melacrino Morelli; 3Complex Structure of Hematology, AO Città della Salute e della Scienza; 4Department of Translational Medicine, Division of Hematology, Universita' del PiemonteOrientale and Azienda Ospedaliero-Universitaria Maggiore della Carità; 5Division of Hematology, Foundation, IRCCS Policlinico San Matteo; 6IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology “Seràgnoli”; 7Onco-Hematology Unit, AOR Villa Sofia-Vincenzo Cervello; 8Hematology and Stem Cell Transplant Unit "Vito Fazzi" Hospital; 9Hematology Unit with BMT, A. O. U. Policlinico “G. Rodolico-San Marco”; 10Hematology Unit, Santo Spirito Civil Hospital; 11Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University; 12Hematology Section, Perugia University Hospital; 13Hematology and Bone Marrow Transplantation Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII; 14SOD Hematology, Azienda Ospedaliera Universitaria Careggi; 15Hematology Department, University of Ancona, Azienda Ospedaliero Universitaria delle Marche; 16SC Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; 17AOU Policlinico Tor Vergata, UOSD Patologie Mieloproliferative; 18ASST Grande Ospedale Metropolitano Niguarda Dipartimento ematologia ed oncologia; 19Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia; 20UCO Hematology, Azienda Sanitaria Universitaria Giuliano Isontina; 21Hematology Unit, AORN Cardarelli Hospital; 22UOC Hematology S. Rosa Viterbo Hospital; 23Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona"; 24IRST IRCCS, Meldola; 25AbbVie srl; 26 IRCCS Humanitas Research Hospital; .

P058 | Ct-DNA-based liquid biopsy of cerebrospinal fluid in an adult with meningeal relapse of acute lymphoblastic leukaemia Ph+

P. Cercola1, D. Guadagnolo1|2 , S. Fazio1, E. Sangiorgi1, F. Proietti Serafini1, I. Fulvi1, L. Gerboni1, G. Proietti1, D. Remotti3, V. Ranucci3, R. Latagliata4, G. Trapè4, C. Mercanti4, G. Topini5, S. Quattrociocchi1, M. Tonizza1, G. Pessina1 | 1UOSD Laboratorio di Genetica Medica Ospedale Santa Rosa ASL Viterbo, 2Department of Molecular Medicine Sapienza University of Rome, 3UOC Anatomia Patologica Ospedale Santa Rosa ASL Viterbo, 4UOC Ematologia Ospedale Santa Rosa ASL Viterbo, 5UOC Diagnostica Clinica Polo Ospedale Santa Rosa ASL Viterbo

P059 | WT1 reduction after induction therapy predicts outcome in AML patients

C. Marzano1, M. Cuccaro1, A. Santoni1, M. Malchiodi1, A. Sicuranza1, M. Rondoni2, G. Marconi2, K. Palombo2, A. Cartocci3, C. Turriziani1, F. Lanza2, M. Bocchia1 | 1Hematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena; 2Hematology Unit, University of Bologna, Ospedale S. Maria delle Croci; 3Department of medical science, surgery and neurosciences, University of Siena, Siena

P060 | Integration of genomic and clinical data in acute myeloid leukemia: actual performance of the Sanger multistage prognostic model

A. Duminuco1, S. Vitale2, A. Nardo1, S. Stella2, M. Massimino2, C. Tomarchio2, F. Di Raimondo1, C. Vetro3, L. Manzella2, G. A. Palumbo1 | 1Hematology Unit, AOU Policlinico "G. Rodolico-San Marco"; 2Center of Experimental Oncology and Hematology, AOU Policlinico "G. Rodolico-San Marco"; 3Hematology and BMT Unit, Hospital of Bolzano SABES-ASDAA, Teaching Hospital of Paracelsus Medical University

P061 | Clinical outcomes of younger adult patients with Philadelphia-negative acute lymphoblastic leukemia, treated in the real-life with a pediatric-like regimen based on GIMEMA LAL1308 protocol: an observational retrospective campus all study

F. Forghieri1, C. Caterina1, D. Lazzarotto2, M. Annunziata3, E. Lugli4, M. Ciccone5, M. Dargenio6, C. Papayannidis7, F. Mosna8, P. Chiusolo9|10, F. Guolo11|12, C. Buquicchio13, S. Cordella1, M. Bonifacio14|15, F. Ferrara3, G. Pizzolo14|15, R. Foà16, A. Candoni1|17, M. Luppi1, A. M. Testi16 | 1Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; 2Clinica Ematologica - Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale; 3Hematology Unit, Hospital “Antonio Cardarelli”; 4Ematologia, Azienda USL - IRCCS di Reggio Emilia; 5UO Ematologia, Dipartimento di Medicine Specialistiche, Azienda Ospedaliero-Universitaria Arcispedale S. Anna; 6S. C. Ematologia, Ospedale Vito Fazzi; 7IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; 8Hematology and Bone Marrow Transplantation Unit BMTU, Hospital of Bolzano SABES-ASDAA, Teaching Hospital of Paracelsus Medical University PMU; 9Hematology Unit, Dipartimento Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli – IRCCS; 10Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Università Cattolica del Sacro Cuore; 11Clinica Ematologica, Dipartimento di Medicina Interna DiMI, Università degli Studi di Genova; 12IRCCS Ospedale Policlinico San Martino; 13Hematology and Bone Marrow Transplant Unit, Ospedale Monsignor R. Dimiccoli. Barletta; 14Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona; 15Department of Medicine, Azienda Ospedaliera Universitaria Integrata di Verona; 16Unità di Ematologia, Dipartimento di Medicina Traslazionale e di Precisione, “Sapienza” Università di Roma; 17Hematology Section, Dipartimento di Medicina Specialistica, Ca' Foncello Hospital

P062 | Interim results of the questionnaire on predisposition to acute lymphoblastic leukemia in the AIEOP-BFM ALL 2017 protocol

L. R. Bettini1, M. Lattuada2, D. Silvestri3, L. Lo Nigro4, N. Bertorello5, R. Parasole6, M.C. Putti7, F. Locatelli8, V. Conter3, M. G. Valsecchi9, A. Biondi1, C. Rizzari1, G. Cazzaniga2|3 | 1Pediatrics, Fondazione IRCCS San Gerardo dei Tintori; 2School of Medicine and Surgery, University of Milano-Bicocca; 3Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori; 4Pediatric Hematology and Oncology Center, Azienda Policlinico G. Rodolico - San Marco; 5Pediatric Hematology-Oncology Unit, Regina Margherita Children’s Hospital; 6Pediatric Hematology and Oncology, AORN Santobono-Pausilipon; 7Pediatric Hemato-Oncology Clinic, Department of Women’s and Children’s Health, University Hospital - University of Padua; 8Department of Onco-Hematology and Cell and Gene Therapy, Bambino Gesù Children’s Hospital; 9Center for Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca and Fondazione IRCCS San Gerardo dei Tintori

P063 | Analysis of the expression profile of long non-codingRNAs in patients affected by T-cell large granular lymphocyte leukemia

G. Pertile1|2, E. Buson1|2, B. Mariotti3, G. Calabretto1|2, E. Rampazzo1|2, R. Crivellari1|2, L. Massarotti1, V. Trimarco1, F. Bazzoni3, M. Facco1, L. Trentin1, G. Semenzato2, A. Teramo1|2, R. Zambello1|2 | 1Department of Medicine, Hematology Branch, University of Padova; 2Veneto Institute of Molecular Medicine - VIMM; 3Section of General Pathology, Department of Medicine, University of Verona, Italy.

P064 | XPO1 mutations drive BCR hyperactivation and early disease progression in chronic lymphocytic leukemia

C. Cosentino1, E. Tissino2, R. Bomben2, T. Bittolo2, F.M. Rossi2, A. Gaglio2, R. Mozzillo2, M. Almasri1, R. Dondolin1, M. Bellia1, S. Rasi1, E. Secomandi1, J. Nabki1, B. Al Deeban1, L. Cividini1, F. Maiellaro1, J. Ghanej1, A. Mahmoud1, S. Kogila1, S. Mouhssine1, N. Maher1, G. Gaidano1, V. Gattei2, A. Zucchetto2, R. Moia1 | 1Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale; 2Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano CRO, IRCCS, Italy.

P065 | Clinical and genomic patterns of disease progression in CLL patients treated with fixed-duration versus continuous targeted therapies

A. Serafin1, F. Angotzi1, A. Bevilacqua1, A. Cellini1, M. D’antiga1, L. Bonaldi2, A. Martines2, E. Albi3, E. Sant’antonio3, F. Martini3, S. De Antoni2, S. Pepe4, I. Cavallari2, A. Noto5, A.M. Frustaci5, F.R. Mauro4, P. Ghia3|6, L. Scarfò3|6, L. Trentin1, A. Visentin1 | 1Hematology Unit, Department of Medicine, University of Padova; 2Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS; 3Strategic Research Program on CLL, IRCCS Ospedale San Raffaele; 4Hematology, Department of Translational and Precision Medicine, "Sapienza" University; 5Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda; 6Medical School, Università Vita-Salute San Raffaele

P066 | STAT3-mediated circular RNAs dysregulation in neutropenic T-large granular lymphocyte leukemia patients

R. Crivellari1|2, E. Rampazzo1|2, C. Vicenzetto1|2, A. Buratin3|4, V.R. Gasparini1|2, E. Gaffo3, G. Calabretto1|2, E. Buson1|2, G. Pertile1|2, L. Massarotti1|2, E. Roncaglia3, V. Trimarco1, M. Facco1, L. Trentin1, G. Semenzato2, A. Teramo1|2, S. Bortoluzzi5, R. Zamebello1|2 | 1Department of Medicine, Hematology Branch, University of Padova; 2Veneto Institute of Molecular Medicine – VIMM; 3Department of Molecular Medicine, University of Padova; 4Department of Biology, University of Padova; 5Department of Surgery, Oncology and Gastroenterology, University of Padova

P067 | Catalase blocking enhances drug sensitivity to BCL-2 inhibitors in chronic lymphocytic leukemia

M. Galasso1|2, V. Salaorni3, S. Gambino1|2, I. Ferrarini1|2, S. Hamidi Alvan3, A. Aparo4, E. Boschiavo1, O. Lovato4, M.E. Carazzolo5, F.M. Quaglia2, C. Visco1|2, M. Krampera1|2, M.T. Scupoli1|4 | 1Department of Engineering for Innovation Medicine, Section of Biomedicine, University of Verona; 2Hematology Unit, Azienda Ospedaliera Universitaria Integrata Verona; 3Department of Diagnostic and Public Health, University of Verona; 4Research Center LURM Interdepartmental Laboratory of Medical Research, University of Verona; 5Department of Medicine, University of Verona

P068 | MiR-146b restoration in T-large granular lymphocyte leukemia: molecular insights for a new therapeutic strategy against neutropenia development

A. Teramo1|2, E. Rampazzo1|2, E. Roncaglia3|4, B. Mariotti5, G. Calabretto1|2, E. Buson1|2, E. Gaffo6, S. Orsi1, R. Crivellari1|2, G. Pertile1|2, V. Trimarco1, M. Facco1, F. Bazzoni4, L. Trentin1, G. Semenzato2, S. Bortoluzzi4, R. Zambello1|2 | 1Department of Medicine, Hematology Unit, University of Padova; 2Veneto Institute of Molecular Medicine - VIMM; 3Department of Biology, University of Padova; 4Computational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padova; 5Department of Medicine, Division of General Pathology, University of Verona; 6Department of Molecular Medicine, University of Padova

P078 | A prospective study on high resolution ultrasound assessment of superficial lymphonodes of CLL patients during BTKi treatment: comparison of dimensional response vs overall ultrasound assessment in general practice

E. Benedetti1|2, M.C. Caparello1, C. Barate3, R. Morganti4, E. Bramanti5, S. Galimberti1 | 1Azienda Ospedaliero Universitaria Pisana, Hematology Unit, Department of Clinical and Experimental Medicine; 2Italian School of Basic and Emergency Ultrasound - SIUMB; 3Ospedale Niguarda Milano; 4Azienda Ospedaliero Universitaria Pisana, Section of Statistics; 5Institute of Chemistry of Organometallic Compounds - ICCOM, Italian National Research Council - CNR

P079 | Assessment by high resolution ultrasound sonography of patients with chronic lymphocytic leukemia treated with BTK inhibitors. Clinical and pharmacoeconomic impact

E. Benedetti1|2, M.C. Caparello1, B. Bruno3, S. Galimberti1, E. Bramanti4, R. Morganti5, E. Capochiani6 | 1Azienda Ospedaliero Universitaria Pisana, Hematology Unit, Department of Clinical and Experimental Medicine; 2Italian School of Basic and Emergency Ultrasound SIUMB; 3Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, University of Torino; 4Institute of Chemistry of Organometallic Compounds ICCOM, Italian National Research Council CNR; 5Azienda Ospedaliero Universitaria Pisana, Section of Statistics; 6Hematology Unit Center for Translational Medicine Azienda USL Toscana NordOvest, Livorno.

P080 | Targeting CK2 disrupts epigenetic plasticity and sensitizes diffuse large B-cell lymphoma cells to the EZH2 inhibitor tazemetostat

I. Haxhiu1|2, A. Yami1|2|3, L. Quotti Tubi1|2, J. Uddin Dekha1|2|3, J. Ceccato1|2, N. Danesin1, G. Scapinello1, M. Carraro1, A. Visentin1, F. Vianello1|2, L. Trentin1, S. Manni1|2, F. Piazza1|2 | 1Hematology Unit, Department of Medicine, University of Padova; 2Veneto Institute of Molecular Medicine; 3Department of Surgery, Oncology and Gastroenterology, University of Padova.

P081 | BTK inhibition induces differential responses of BCR signaling in basal or stimulated conditions in mantle cell lymphoma

S. Gambino1|2, A. Aparo3, M. Galasso1|2, A. Jafari Kia3, V. Salaorni4, O. Lovato3, M.E. Carazzolo5, F.M. Quaglia2, I. Ferrarini1|2, M.C. Vegliante6, R. Moia7, G. Gaidano7, M. Krampera1|2, C. Visco1|2, M.T. Scupoli1|3 | 1Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine, University of Verona; 2Hematology and Bone Marrow Transplant Complex Operative Unit - UOC, Department with Integrated Activity - DAI - of General Medicine, University Hospital- AOUI - of Verona; 3Research Center LURM-Interdepartmental Laboratory of Medical Research, University of Verona; 4Department of Diagnostic and Public Health, University of Verona; 5Department of Medicine, University of Verona; 6Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori "Giovanni Paolo II"; 7Department of Translational Medicine, Division of Hematology, University of Piemonte Orientale

P082 | Feasibility of immunoglobulin gene rearrangement tracking on circulating tumor DNA as an outcome predictor in primary mediastinal B-cell lymphoma

G.M. Assanto 1|2|3, I. D'Antuono 1, L. Donzelli 1, V. Bellomarino 1, I. Della Starza 1|4, M. Antonacci 1, D. Cardinali 1, M. Ansuinelli 1, L. Petrucci1|3, A. Di Rocco1, I. Del Giudice1, M. Martelli1 | 1Hematology, Department of translational and precision medicine, Sapienza University of Rome; 2Department of Molecular Medicine, Sapienza University of Rome; 3AOU Policlinico Umberto I; 4AIL Roma Odv, Italy.

P083 | The lncRNA MTAAT regulates PD-L1 trafficking via ARF6 in T-cell lymphoma: implications for immunotherapy

S. Mallia1, G. Gambarelli1|2, M. Zanelli3, B. Donati1, D. Fiore4, I. Tamagnini3, F. Torricelli1, P. Di Chiaro1, F. Reggiani1, N. Puccio1, F. Sanguedolce5, S. Ascani6, S. Luminari7, F. Merli7, A. Neri8, A. Ciarrocchi1, V. Fragliasso1 | 1Laboratorio di Ricerca Traslazionale dell'AUSL-IRCCS di Reggio Emilia; 2Medicina Clinica e Sperimentale Ph. D. Program dell'Università di Modena e Reggio Emilia, 3Unità di Patologia dell'AUSL-IRCCS di Reggio Emilia, 4Dipartimento di Medicina Molecolare e Biotecnologia Medica dell'Università Federico II, 5Unità di Patologia Policlinico Università di Foggia, 6Unità di Patologia dell'Azienda Ospedaliera di Santa Maria di Terni, 7Unità di Ematologia dell'AUSL-IRCCS di Reggio Emilia, 8Direzione Scientifica dell'AUSL-IRCCS di Reggio Emilia

P084 | Resistance to BET protein inhibitors is orchestrated by protein kinase CK2 in mantle cell lymphoma

S. Manni1|2, J. Uddin Dekha1|2|3, L. Marcato1|2, A. Yami1|2|3, L. Quotti Tubi1|2, I. Haxhiu1|2, A. Fregnani1|2, J. Ceccato1|2, N. Danesin1, G. Scapinello1, M. Carraro1, A. Visentin1, F. Vianello1|2, L. Trentin1, F. Piazza1|2 | 1Hematology Unit, Department of Medicine, University of Padova; 2Veneto Institute of Molecular Medicine; 3Department of Surgery, Oncology and Gastroenterology, University of Padova

P085 | Rewiring tumor-driven inflammation to restore immune surveillance in mantle cell lymphoma

J. Uddin Dekha1|2|3, J. Ceccato1|2, A. Yami1|2|3, L. Quotti Tubi1|2, I. Haxhiu1|2, M. Fantuz2, N. Danesin1, G. Scapinello1|2, M. Carraro1, F. Vianello1|2, L. Trentin1, F. Piazza1|2, S. Manni1|2 | 1Hematology Unit, Department of Medicine, University of Padova; 2Veneto Institute of Molecular Medicine; 3Department of Surgery, Oncology and Gastroenterology, University of Padova

P086 | ECM–DLBCL interactions drive reversible ibrutinib resistance in a 3D bone model

J. Ceccato1|2, M. Piazza1, G. Gualtiero1|2, S. Carraro1, F. Cinetto3, C. Biz4, M. Pizzi5, L. Quotti Tubi1|2, A. Yami1|2, J. Uddin Dekha1|2, S. Manni1|2, F. Piazza1|2, A. P. Dei Tos5, P. Ruggieri5, L. Trentin1, F. Vianello1 | 1Hematology Unit, Department of Medicine, University of Padua; 2Laboratory of Myeloma and Lymphoma Pathobiology, Veneto Institute of Molecular Medicine VIMM; 3Internal Medicine and Allergology and Clinical Immunology Units, Treviso Ca' Foncello Hospital; 4Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua; 5Orthopedics and Orthopedic Oncology, Department of Surgery, Oncology and Gastroenterology DiSCOG, University-Hospital of Padova

P087 | Real-life experience with the POLA-R-CHP regimen in diffuse large B-cell lymphoma: a retrospective analysis

L. Scalise1, L. Pezzullo2, D. Pastore3, F. Merchionne3, G.R. Mansueto4, G. Pietrantuono4, E. Martino5, M. Gentile5, M. Rossi1 | 1Azienda Osp. Univ. Renato Dulbecco Ematologia; 2AOU San Giovanni Di Dio UOC Ematologia; 3UOC di Ematologia Osp. A. Perrino; 4IRCCS C.R.O. B Ematologia; 5UOC Ematologia Azienda Ospedaliera Cosenza, Italy.

P091 | Dissection of NEAT1’s role in transcriptional regulation reveals actionable targets in high-risk multiple myeloma

N. Puccio1, C. Boni1, F. Torricelli1, E. Vitale1, E. Taiana2, V. Fragliasso1, S. Mallia1, G. Gambarelli1|3, N. Bolli2|4, N. Amodio5, R. Piva6, S. Luminari7, A. Ciarrocchi1, A. Neri8 | 1Azienda USL-IRCCS di Reggio Emilia, Laboratory of Translational Research; 2Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Hematology Unit; 3University of Modena and Reggio Emilia, Clinical and Experimental Medicine PhD Program; 4University of Milan, Department of Oncology and Hemato-oncology; 5Department of Clinical and Experimental Medicine, Magna Graecia University; 6University of Turin, Department of Molecular Biotechnology and Health Sciences; 7Azienda USL-IRCCS di Reggio Emilia, Hematology Unit; 8Azienda USL-IRCCS di Reggio Emilia, Italy.

P095 | Tumor burden and immune microenvironment influence response to anti-bcma bispecific antibodies in relapsed/refractory multiple myeloma

E. Tofacchi1, C. Aquilina1, A.M. Corsale1, M. Speciale1, M. Biondo1, A. Romano1, E. Gigliotta1, A. F. Terranova1, F. Dieli2, S. Meraviglia2, A. Gallo3, F. Accardi4, S. Grimaudo1, S. Siragusa1, C. Botta1 | 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties ProMISE "G. D'Alessandro", University of Palermo; 2Department of Biomedicine, Neuroscience and Advanced Diagnosis, University of Palermo; 3Department of Research, IRCCS ISMETT - Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione-, UPMC; 4U. O. C di Oncoematologia, Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello, Italy.

P096 | Bcma genotypes in relation to prognosis and induction and maintenance therapy in multiple myeloma patients

M.L. Del Giudice1, M. Magrini2, M. Vitiello2, S. Mori2, R. Silvestri2, F. Rea2, M. Cipollini2, R. Foddis3, S. Galimberti1, F. Gemignani2, S. Landi2, G. Buda1 | 1Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa; 2Genetic Unit, Department of Biology, University of Pisa; 3Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa

P098 | Glutamine-dependent anaplerotic rewiring with pyruvate carboxylase down-tuning underlies proteasome inhibitors resistance in multiple myeloma

D. Tibullo1, L. Longhitano1, J Ferrigno1, E. La Spina1, G.N. Conti1, F. Bellia1, A.M. Amorini1, S. Giallongo2, A. Duminuco3, G.A. Palumbo3, I. Dulcamare4, C. Conticello5, D. Cambria4, D. Calvo1, T. Zuppelli1, Me Gallo Cantafio5, G. Li Volti1, N. Amodio5, Di Raimondo4, A. Romano4, C. Giallongo1 | 1Department of Biomedical and Biotechnological Sciences, University of Catania; 2Faculty of Medicine and Surgery, University of Enna “Kore”; 3Department of Medical and Surgical Sciences and Advanced Technologies “G. F. Ingrassia”, University of Catania; 4Department of General Surgery and Medical-Surgical Specialties- University of Catania, Division of Haematology; 5Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Italy.

P099 | Exploring the transcriptional profile of dis3 can unravel new targeting strategies in multiple myeloma

C. Boni1, N. Puccio1, F. Torricelli1, E. Vitale1, S. Mallia1, I. Craparotta2, L. Di Rito2, V. Manicardi1, V. Fragliasso1, E. Taiana3, A. Ciarrocchi1, A. Neri1|4 | 1Laboratorio di ricerca traslazionale, AUSL-IRCCS; 2Dipartimento di Oncologia, Istituto di Ricerche Farmacologiche Mario Negri IRCCS; 3Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; 4Direttore scientifico, AUSL-IRCCS

P100 | Enhanced nad biosynthesis and ppp activation drive venetoclax resistance in multiple myeloma: therapeutic reversal by nampt inhibition

I. Traverso1, D. Soncini1|2, G. Giorgetti2, S. Ravera3, J. Ivanisevic4, M. Garibotto2, M. Gallo1, F. Guolo1|2, A. Cagnetta2, R.M. Lemoli1|2, M. Cea1|2 | 1Clinic of Hematology, Department of Internal Medicine and Medical Specialties DiMI, University of Genoa; 2IRCCS Ospedale Policlinico San Martino; 3Department of Experimental Medicine DIMES, University of Genoa, Italy 4Metabolomics Unit, Faculty of Biology and Medicine, University of Lausanne, Switzerland.

P101 | The long term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients

M. Bernardi1, G. Todaro1, G. Sammarelli1, N.T. Iannozzi2, A. Poletti2, M. Scita1, A.B. Dalla Palma1, S. Ricci1, C. Sitzia2, P. Storti2, N. Giuliani1|2 | 1Programma Mieloma Multiplo e Gammopatie Monoclonali, U. O. Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma; 2Dipartimento di Medicina e Chirurgia, Università di Parma

P102 | Odissey: a multicenter, observational study of multiple myeloma patients who discontinued therapy in clinical practice

N. Sgherza1, G. Di Carlo2, P. Curci1, O. Battisti1, G. Palumbo3, C. De Risi4, A. G. Solimando5, G. Palazzo6, C. Germano7, A. Quinto8, G. Mele9, D. De Novellis10, M. Gentile11|12, P. Musto1|2 | 1Hematology and Stem Cell Transplantation Unit, AOUC Policlinico; 2Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine; 3Hematology Unit, AOU Policlinico Riuniti di Foggia; 4Haematology and Transplant Unit, “V. Fazzi” Hospital; 5Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area - DiMePRe-J, School of Medicine, University of Bari Aldo Moro; 6Hematology Unit, “G. Moscati” Hospital; 7Hematology Unit,“Mons. Dimiccoli” Hospital; 8Hematology and Cell Therapy Unit, IRCCS “G. Paolo II”; 9Hematology Unit,“A. Perrino” Hospital; 10Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona"; 11Hematology Unit, Department of Onco-Hematology, AO of Cosenza; 12Department of Pharmacy, Health and Nutritional Science, University of Calabria

P103 | Partial inhibition of nampt restores metabolic vulnerability and synergizes with anti-myeloma agents in multiple myeloma

G. Giorgetti1, I. Traverso2, D. Soncini1|2, F. Lai1, B. Antonioli2, M. Garibotto1, F. Guolo1|2, A. Cagnetta1, D. Fenoglio1|3, S. Ravera1|4, E. Marcenaro1|4, M. Greppi4, S. Bruzzone1|4, A. Benzi4, W. Min5, M. Shelle5, R.M. Lemoli1|2, M. Cea1|2 | 1IRCCS Ospedale Policlinico San Martino; 2Clinic of Hematology, Department of Internal Medicine and Medical Specialties DiMI, University of Genoa; 3Centre of Excellence for Biomedical Research, Department of Internal Medicine, University of Genoa; 4Department of Experimental Medicine DIMES, University of Genoa; 5Remedy Plan Therapeutics

P104 | Soluble bcma mirrors bone marrow disease burden and predicts outcome in multiple myeloma patients

D. Soncini1|2, I. Traverso1, G. Giorgetti2, A.E. Laserra1, E. Catini1, F. Guolo1|2, M. Garibotto2, A. Cagnetta2, R.M. Lemoli1|2, M. Cea1|2 | 1Clinic of Hematology, Department of Internal Medicine and Medical Specialties DiMI, University of Genoa; 2IRCCS Ospedale Policlinico San Martino

P105 | Immunosuppressive and biological drugs do not influence progression of mgus or smoldering multiple myeloma in patients with concomitant autoimmune disorders: preliminary data from a retrospective, single-center study

N. Sgherza1, O. Magazzino2, P. Curci1, E. Resta3, O. Battisti1, A. Vitucci1, A. V. Russo Rossi1, F. Iannone4, P. Musto1|2 | 1Hematology and Stem Cell Transplantation Unit, AOUC Policlinico; 2Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine; 3Department of Clinical and Molecular Medicine, Sapienza University; 4Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine

P106 | Cd20 positive multiple myeloma: is it a different entity?

V. Panichi1, G. Tomei2, G. De Angelis2, E. Palamides1, M. G. Chavez3, L. Bassi4, M. Poscente4, R. Isidori4, G. Topini1, C. Stefanizzi2, F. Natalino2, R. Agrippino3, G. Trapè2, A. andriani2, M. Montanaro2, M. A. Silvestri1, G. Pessina4, R. Latagliata2 | 1UOC Diagnostica Clinica, Laboratorio di Citofluorimetria, Ospedale Santa Rosa, ASL Viterbo; 2UOC Ematologia, Ospedale Santa Rosa; ASL Viterbo; 3Servizio di Medicina Trasfusionale SIMT, Ospedale Santa Rosa, ASL Viterbo; 4UOSD Laboratorio Genetica Medica, Ospedale Santa Rosa, ASL Viterbo

P107 | Karyotype evaluation according to patient age in multiple myeloma

M. Poscente1, L. Bassi1, R. Isidori1, F. Proietti Serafini1, G. Tomei2, G. De Angelis2, G. Trape’2, M. Montanaro2, M. Lo Presti1, F. Di Palma1, S. Peruzzi1, M. Tonizza1, I. Bracoloni1, V. Panichi3, G. Topini3, R. Latagliata2, G. Pessina1 | 1UOSD Laboratorio Genetica Medica, Ospedale Santa Rosa, ASL Viterbo; 2UOC Ematologia, Ospedale Santa Rosa, ASL Viterbo; 3UOC Diagnostica Clinica, Laboratorio di Citofluorimetria, Ospedale Santa Rosa, ASL Viterbo

P108 | Is there a prognostic and diagnostic role of myc rearrangements in multiple myeloma at diagnosis by fish? description of 3 clinical cases

R. Isidori1, L. Bassi1, M. Poscente1, F. Proietti Serafini1, M. Tonizza1, G. Gaetani1, D. Dinarelli1, F. Cesaretti1, E. Sangiorgi1, F. Di Palma1, V. Panichi3, G. Topini3, G. Tomei2, G. De Angelis2, G. Trapè2, M. Montanaro2, R. Latagliata2, G. Pessina1 | 1UOSD Laboratorio Genetica Medica, Ospedale Santa Rosa, ASL Viterbo; 2UOC Ematologia, Ospedale Santa Rosa, ASL Viterbo; 3UOC Diagnostica Clinica, Laboratorio di Citofluorimetria, Ospedale Santa Rosa, ASL Viterbo

P112 | Igfbp-6 as a potential regulator of platelet procoagulant activity

L. Bury1, E. Falcinelli1, E. Petito1, L. Leijonancker2, P. Gresele1, A. Liso3 | 1Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia; 2Pixelgen Technologies AB; 3Department of Medicine and Surgery, Hematology/Oncology Unit, Terni Hospital, University of Perugia, Italy.

SIES: Scholarship session

1